Adenosine monophosphate-activated protein kinase as a potential target for synthetic chalco-naringenin analogs and putative therapeutic applications. by Nyane, Ntsoaki Anna.
i 
 
  
 
 
 
 
 
 
Adenosine monophosphate-activated protein kinase as a potential target for 
synthetic chalco-naringenin analogs and putative therapeutic applications  
 
 
                                                    
 
                                          
 
  
  ‘Nyane Anna Ntsoaki                                  
                                                            216056740 
 
 
 
 
 
 
 
 
    
 
 
  A thesis submitted in partial fulfillment of the requirements for the award of the degree of  
                                            Masters in Pharmacy 
College of Health Sciences  
2017 
                                                                                                          
 
 
ii 
 
AMPK as a potential target for synthetic chalco-naringenin analogs and putative 
therapeutic applications  
 
 
 
 
 
 
 
By 
‘NYANE ANNA NTSOAKI 
 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfillment of the requirements for the award of the degree of  
MASTERS IN PHARMACY 
 (PHARMACOLOGY)  
 
 
Department of Pharmacology, Discipline of Pharmaceutical Sciences, School Of Health 
Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa  
 
As the candidate’s supervisor, I have approved this dissertation for submission 
Signed:                                           Name:                                Date 
 
 
 
 
 
 
 
iii 
 
DECLARATION 
 
    I, Ntsoaki Anna ‘Nyane, declare that: 
 
1. The research reported in this thesis, except where indicated, and is my own original 
research. 
2. This thesis has not been submitted for any degree or examination at any other 
university. 
3. This thesis does not contain other persons’ data, pictures, graphs or other information, 
unless specifically acknowledged as being sourced from other persons. 
4. This thesis does not contain other persons’ writing, unless specifically acknowledged 
as being sourced from other researchers. Where other written sources have been quoted, 
then: 
a) Their words have been re-written but the general information attributed to them has 
been referenced. 
b) Where their exact words have been used, then their writing has been placed in italics 
and inside quotation marks, and referenced. 
5. This thesis does not contain text, graphics or tables copied and pasted from the internet 
unless specifically acknowledged, and the source being detailed in the thesis and in the 
reference sections. 
 
Signed:                                                                    Date: 
                        
 
 
 
 
 
 
 
 
                                                      
 
 
 
 
 
iv 
 
PREFACE 
 
The study represents the original work of the author and has not been submitted to another 
university in any other form. This study has been submitted in fulfilment of the academic 
requirements for obtaining a Master’s Degree in Pharmacy (Pharmacology).The use of 
information from other sources in this dissertation has been duly acknowledged in the text and 
reference section.  
 
 
 
 
 
…………………………………………… 
Ntsoaki ‘Nyane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
 
I take this opportunity to express my deepest gratitude to the almighty God for his grace and 
giving me strength to do this research and seeing it to completion. Appreciation to my 
supervisor for accepting me into his research group and for giving me the unique opportunity 
of professional growth and his guidance during my study. I would also like to extend my 
heartfelt appreciation to my parents who taught me there is nothing more important in life than 
good education and have always encouraged me with their patience, encouragement and 
support in the hard moments of this period. To my family, friends and loved ones for 
unconditional support, prayers and encouragement. To my friend, Nyika Mtemeri who gave 
me all the support I needed throughout the research, thank you. 
 
I thank Dr V Bangalee for being a mentor and advisor all the time. My deepest gratitude to my 
colleagues at the Pharmacology department for creating an excellent working atmosphere and 
for their help, knowledge and advices on the practical field assistance and encouragement. To 
Ms. Mbili in the Department of Physiology thank you so much for your kind assistance. The 
discipline of Pharmaceutical Sciences for awarding me several invaluable opportunities during 
my time as postgraduate student, I thank you always. 
 
I am thankful to College of Health Sciences at the University of KwaZulu-Natal for financial 
support for this study. 
 
 
 
 
 
                                
 
 
vi 
 
 
PUBLICATIONS/ MANUSCRIPTS 
 
1.  ‘Nyane NA, Tlaila TB, Malefane TG, Ndwandwe DE, Owira PMO. Metformin-like 
antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and 
pharmacological insights. Eur J Pharmacol.  2017 May 15; 803:103-111. 
2. Christine Driver, Julia Achieeng Hayangah, Ntsoaki Annah ‘Nyane, Peter Mark Oroma 
Owira. Metformin with insulin relieves oxidative stress and confers renoprotective in 
type 1 diabetes in vivo: Journal of Nephropathology. (doi: 10.25171/jnp.2017.xx) 
3.  Christine Driver, Kayode Bamitale, Mehnaaz Olla, Ntsoaki Nyane, Peter Owira. 
Metformin: The magic bullet in Cardiovascular Disease Complications? Updates on 
current experimental evidence: Journal of Clinical and Experimental Pharmacology 
and Physiology.CEPP-17-0395. 
 
 
                                      CONFERENCE ABSTRACTS 
 
 
‘NYANE, N.A 
 
1. UKZN College of Health Sciences research symposium (September 2016), Durban, 
South Africa, (Awarded first-prize R30, 000.00 International Travel Voucher) (AMPK as 
a potential target for synthetic chalco-naringenin analogs and putative therapeutic 
applications).  
2.  International Diabetes Federation's Annual Congress 4th - 8th December 2017 Abu 
Dhabi, UAE, (AMPK as a potential target for synthetic chalco-naringenin analogs and 
putative therapeutic applications).  
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF ABBREVIATIONS 
 
AACE     American Association of Clinical Endocrinologists  
ACAT   Acyl-CoA: cholesterol acyltransferase  
ACC   Acetyl-CoA Carboxylase 
ACEIs   Angiotensin-Converting Enzyme Inhibitors  
ADA                                    American Diabetes Association  
ADP    Adenosine diphosphate 
AGEs                            Advanced Glycation End-products  
AMP    Adenosine monophosphate 
AMPK    Adenosine monophosphate –activated protein kinase 
ANOVA        One-Way Analysis of Variance  
ARBs   Angiotensin Receptor Blockers  
ATP    Adenosine Triphosphate 
CAD   Coronary Artery Disease  
CaMKKβ                                 Ca2+/Calmodulin-dependent Protein Kinase Kinase beta  
cAMP    Cyclic Adenosine Monophosphate 
 CBS                                       Cystathionine β-Synthase  
 CCM                                       Cell Culture Medium  
CREB    cAMP Response Element-Binding protein 
DAG                          Diacyl Glycerol  
DCM    Diabetic Cardiomyopathy  
DKA                                    Diabetic Ketoacidosis  
DKD   Diabetic Kidney Disease  
DMEM                                Dulbecco's Modified Eagle's medium  
DMSO    Dimethyl Sulfoxide 
DN                                          Diabetic Nephropathy 
DPP-4   Dipeptidyl Peptidase 4  
DR                                          Diabetic Retinopathy 
DSP   Distal Symmetric Polyneuropathy  
EASD   European Association for the Study of Diabetes   
ECACC       European Collection of Cell Cultures  
EGCG    Epigallocatechin Gallate  
eGFR                   estimated Glomerular Filtration Rate  
viii 
 
ELISA                                Enzyme Linked-Immuno-Sorbent Assay 
ER   Endoplasmic Reticulum  
ESRD        End-Stage Renal Disease   
ET-1     Endothelin-1 
F-6-P   Fructose-6-Phosphate  
FBG   Fasting Blood Glucose 
 FBS                         Fetal Bovine Serum  
FDA                     Food and Drug Administration  
FFA                                         Free Fatty Acids  
FOXO1   Fork Head Box Protein O1  
FSH   Follicle Stimulating Hormone  
FT-IR    Fourier Transform Infrared spectroscopy                           
G-6-P   Glucose-6-Phosphate  
G6Pase                                Glucose 6-phosphatase   
GAD      Glutamic Acid Decarboxylase  
 GBD   Glycogen Binding Domains  
GDM   Gestational Diabetes Mellitus  
GFAT    Fructose-6 Phosphate Aminotransferase  
GFR   Glomerular Filtration Rate 
GLP1   Glucagon-Like Peptide 1 
GLUT-2   Glucose Transporter Type 2 
GLUT4                                    Glucose Transporter Type 4 
GTIs                                Genital Tract Infections  
HbA1c                                     Glycated Hemoglobin 
HDL-c   High Density Lipoprotein Cholesterol  
HHS                                     Hyperglycemic Hyperosmolar State  
HLA    Human histocompatibility 
HMG-CoA reductase  3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A reductase  
HNF   Hepatocyte Nuclear Transcription  
HO-1   Heme Oxygenase-1  
ICA   Islet Cell Antibody  
ICAM-1   Intercellular Adhesion molecule-1 
IDF    International Diabetes Federation 
IFN-γ)                                      Interferon gamma 
ix 
 
IGF-1   Insulin Growth Factor-1  
IL-2                                          Interleukin-2 
IPF   Insulin Promoter Factor  
IR     Insulin Resistance  
IRS-1   Insulin Receptor Substrate-1  
IRS-2   Insulin Receptor Substrate-2  
LDL         Low Density Lipoprotein  
LDL-C   Low Density Lipoprotein Cholesterol 
LKB1    Liver Kinase B1 
LVH    Left Ventricular Hypertrophy  
MALA                      Metformin-Associated Lactic Acidosis  
 MI   Myocardial Infarction  
 MMV                                    Molegro Molecular Viewer  
MODY   Maturity Onset Diabetes of the Young  
MPTP   Mitochondrial Permeability Transition Pore  
mTOR   Mammalian Target of Rapamycin  
 MTT                                       3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltretrazolium bromide  
MTTP   Microsomal Triglyceride Transfer Protein  
NAD+   Nicotinamide Adenine Dinucleotide  
NADPH   Nicotinamide Adenine Dinucleotide Phosphate  
NMR    Nuclear Magnetic Resonance 
NO   Nitric Oxide  
NPH   Neutral Protamine Hagedorn  
Nrf2  Nuclear Factor erythroid 2-Related factor 2  
OCT1    Organic Cation Transporter 1 
OGTT                                  Oral Glucose Tolerance Test 
PAI-1   Plasminogen Activator Inhibitor-1  
PCOS   Polycystic Ovarian Syndrome  
PDGF    Platelet-Derived Growth Factor 
PEPCK   Phosphoenol pyruvate carboxykinase 
PGC1α   Peroxisome proliferator activated receptor gamma coactivator 1- 
alpha 
PI3-k                                     Phosphoinositide -3- kinase  
x 
 
PI3K/PKB/Akt    Phosphatidylinositol- 3-kinase/protein kinase B/akt  
PKA                                        Protein Kinase A 
PKC                                        Protein Kinase C  
PP2C                     Protein Phosphatase 2C  
PPAR δ   Peroxisome Proliferator-activated Receptor δ  
RAAS   Renin-Angiotensin-Aldosterone System  
RAGE   Receptor for Advanced Glycation End products  
RCC1     Respiratory Chain Complex 1 
RISK   Reperfusion Injury Salvage Kinase  
RLU                                        Relative Light Units  
RNA    Ribonucleic Nucleic Acids  
ROS           Reactive Oxygen Species  
RT-PCR   Real Time Polymerase Chain Reaction 
SGLT2   Sodium Glucose co-Transporter 2 
 SH2   Src Homology 2  
SREBP1    Sterol Regulatory Element-Binding Protein-1 
STZ   Streptozotocin 
T1D    Type 1 Diabetes  
T2D    Type 2 Diabetes  
TG   Triglycerides 
TGF-1   Transforming Growth factor-1  
TGF-β   Transforming Growth Factor-β 
Thr                                         Threonine                                  
TLC                          Thin Layer Chromatography   
TMB                                      3, 3′, 5, 5′-Tetramethylbenzidine  
TNF-α          Tumor Necrosis Factor alpha  
TNF-β   Tumor Necrosis Factor beta  
TORC2  Transducer of Regulated CREB activity 2 
UDP   Uridine Diphosphate  
UKPDS   United Kingdom Prospective Diabetes Study  
UTIs                                   Urinary Tract Infections  
VEGF    Vascular Endothelial Growth Factor 
VLDL   Very Low Density Lipoproteins  
VSMC   Vascular Smooth Muscle Cells 
xi 
 
LIST OF FIGURES 
 
Figure 1 Global burden of diabetes by IDF regions (image adapted from the 
International Diabetes Federation, Diabetic Atlas 2015)  
Figure 2 Etiology of Type 1 Diabetes 
Figure 3  Pathogenesis of Type 2 Diabetes characterized by impaired secretion and 
insulin resistance 
Figure 4 Insulin signaling pathway 
Figure 5      Pathophysiology of diabetic ketoacidosis 
Figure 6 Mechanisms by which hyperglycemia induces diabetic vascular complications 
Figure 7 Proposed mechanism of action of metformin 
Figure 8            Skeleton structure of flavonoids 
Figure 9  Chemical structures of A: metformin and B: naringenin. ChemDraw, 
PerkinElmer® 
Figure 10         Enzymatic hydrolysis of naringin 
Figure 11       Regulation of AMPK activation 
Figure 12  AMPK regulation and metabolism in skeletal muscle 
Figure 13  Claisen-Schmidt reaction, chalcone synthesis 
Figure 14         Flow diagram of experimental protocol 
Figure 15          5b-AMPK interaction (hydrophobic interactions shown in green) 
Figure 16 13C-NMR & 1H-NMR spectra of compound 5b 
Figure 17  13C-NMR &1H-NMR spectra of compound 5k 
Figure 18  The IR spectra of 5b & 5k 
Figure 19  Cell viability measured by MTT assays, expressed as percentage of the 
controls following exposure to 5b (10-750 μM) in cell culture media for 12, 
24 and 48 hours on C2C12. 
Figure 20       Cell viability measured by MTT assays, expressed as percentage  of the controls 
following  exposure to 5k (10-750 μM)  in cell culture media for 12, 24 and 
48 hours on C2C12.     
Figure 21 Cell viability measured by MTT assays, expressed as percentage of the 
controls following exposure to 5b (10-750 μM) in cell culture media for 12, 
24 and 48 hours on Chang cell lines. 
xii 
 
Figure 22           Cell viability measured by MTT assays, expressed as percentage of the 
controls following exposure to 5k (10-750 μM) in cell culture media for 12, 
24 and 48 hours on Chang cell lines. 
Figure 23   Unknown concentrations of pAMPK interpolated from standard curve using 
quadratic curve fit, (dotted lines showing the 95% CI asymptotic). 
Figure 24     Expression of pAMPK after exposure to naringenin, metformin and chalcones 
on Chang cell lines after 48 hours incubation. Cells harvested, lysed and equal 
amount of proteins were used for ELISA with specific antibody recognizing 
phosphorylated Thr 172. 
Figure 25  Expression of pAMPK after exposure to naringenin, metformin and chalcones 
on C2C12 cell lines after 48 hours incubation. Cells harvested, lysed and equal 
amount of proteins were used for ELISA with specific antibody recognizing 
phosphorylated Thr 172. 
Figure 26  Metformin concentrations plotted against the activities of phosphorylated 
AMPK-α in Chang and C2C12 cell lines, respectively and : calculated Area-
Under-the Curve expressed as AUC units (µg/ml X mM). * p<0.05 compared 
to Chang cells. 
Figure 27  Concentrations of naringenin and its chalcones 5b and 5k plotted against the 
activities of phosphorylated AMPK in Chang and C2C12 cell lines, 
respectively and : Calculated Area-Under-the Curve expressed as AUC units 
(µg/ml X mM). *p<0.05 compared to Chang cells; # p<0.05 compared to Nar-
Chang cells; ^ p<0.05 compared to NAR-C2C12 cells. 
Figure 28  Glycogen standard calibration curve using fluorometric assay (dotted lines 
showing the 95% CI asymptotic). 
  Glycogen synthesis in Chang liver cells that were treated for 24 h with 
metformin, naringenin, and chalcones respectively. Data presented as mean ± 
SEM, each carried out in triplicates and glycogen content was measured by 
spectrophotometer to obtain optical densities. 
Figure 29        Glycogen synthesis in C2C12 cells that were treated for 24 h with metformin,   
naringenin, and chalcones respectively. Data presented as mean ± SEM each 
carried out in triplicates and glycogen content was measured by 
spectrophotometer to obtain optical densities. 
 
 
xiii 
 
LIST OF TABLES 
 
Table 1 Drugs clinically used for the treatment of T2D 
Table 2          Binding free energies of ligands docked onto AMPK (PDB code: 4CFH) 
Table 3  Calculated IC50 values from 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltretrazolium bromide (MTT) assays after the C2C12 cells were treated 
with 5b (2-chlorophenyl) and 5k (2, 3-dimethoxyphenyl) at three different time 
intervals 
Table 4  Concentrations (pAMPKα (µg/ml) from standard curve  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
ABSTRACT  
Introduction: Diabetes mellitus is a multifactorial chronic metabolic disorder that is 
characterized by defects in endogenous insulin secretion or action, or both, resulting in chronic 
hyperglycemia, a clinical hallmark of diabetes. Metformin is currently the first-line drug of 
choice for the treatment of type 2 diabetes (T2D), being prescribed to at least 120 million 
people worldwide. It exerts its antidiabetic effects by reducing hepatic glucose production and 
increased peripheral glucose utilization through activation of AMP-activated protein kinase 
(AMPK). However, despite significant gains with metformin as a monotherapy in T2D, some 
patients experience gastrointestinal disturbances and lactic acidosis although the latter is very 
rare. Moreover, some patients still fail to achieve optimum glycemic control when treated on 
metformin only. Naringenin, a flavonoid exerts its antidiabetic effects by inhibition of 
gluconeogenesis through upregulation of AMPK, hence metformin-like effects. Because of 
these similar pharmacological effects between naringenin and metformin, our laboratory 
synthesized analogs of chalco-naringenin compounds which could be more permeable to the 
plasma membrane and hence putatively increased pharmacological effects.  
Aims: To identify AMPK as a potential target of synthetic chalco-naringenin analogs and 
putative therapeutic applications.  
Methods: A novel series of 4-[(cyclopropylcarbonyl)amino] chalco-naringenin analogs, 
compound 5a to 5k, were synthesized and characterized by IR, 1H-NMR and 13C-NMR. In 
silico screening of the compounds was conducted to evaluate potential antidiabetic activity of 
the novel chalco-naringenin series. Compounds 2-chlorophenyl (5b) and 5k (2,3-
dimethoxyphenyl) had highest binding affinity to AMPK hence were chosen for a study. 
C2C12 and Chang cells were cultured in dulbecco's modified eagle medium (DMEM) and 
eagle's minimum essential medium (EMEM) media, respectively, allowed to grow to 80% 
confluence, and then exposed to different concentrations. 
MTT assay was used to determine cell viability and chalcones were subjected for 12, 24 and 
48 hours at concentrations (10-750 µM). Cells were exposed to metformin (2-10 mM), 
naringenin (50-500 µM) and chalcones (10-500 µM) for 48 hours and further subjected to 
phospho-AMPKα (Thr172) sandwich ELISA Kit to determine phosphorylation of AMPK. To 
measure the amount of glycogen in cells after exposure to metformin, naringenin and chalcones 
for 48 hours, cells were harvested (1x106 per mL) and the glycogen assay performed according 
to Seifter et al. (1950). 
Results: A chalcone series of eleven compounds were successfully synthesized using the 
Claisen-Schmidt reaction. The absorbance values and peaks observed on the IR spectra 
xv 
 
confirmed the different functional groups observed on the compounds. The synthesized 
compounds were also characterized through 13C-NMR and 1H-NMR spectroscopy. 
The 13C-NMR spectras indicated the presence of the CH2 group of the cyclopropylcarbonyl  
amide and there were certain distinct peaks on the spectras that identify carbon atoms found on 
the compounds. In 1H-NMR, the chemical shift for all the CH2 groups on the cycloalkane 
resonated around δ 1,16 – 0,80 ppm as multiplets, while the other CH multiplet resonated 
around δ 1,62 – 1,58 ppm. Docking scores of the chalco-naringenin series suggested a good 
binding affinity of these compounds to AMPK, with compound 5b showing the highest binding 
affinity to AMPK. Cell viability as determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assays were found to be dose-dependent for all 
compounds and compound 5k exerted reduced cell viability as compared to 5b. Furthermore, 
compound 5b presented with higher IC50 values compared to 5k. The effects of chalcones on 
AMPK phosphorylation were potentiated by co-treatment with metformin or naringenin. 
Metformin, naringenin and chalcone 5b significantly reduced synthesis of glycogen as 
compared to control (p < 0.05). 
Conclusions: Chalco-naringenin analogs showed potential in expression of AMPK through 
computational chemistry, however in the in vitro model the effects of chalcones on AMPK 
were potentiated by metformin and naringenin. The chalcones could further be explored for 
their potential on AMPK activity on primary hepatocytes and/ or in vivo studies.  
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Chapter One 
1.0 Introduction  
1.1 Epidemiology of Diabetes Mellitus 
Globally, 642 million people are estimated to have diabetes by the year 2040 compared to 415 
million people currently living with diabetes according to International Diabetes Federation 
(IDF) (Fig. 1) [1]. In sub-Saharan Africa, 14.2 million people aged 20-79 had diabetes in 2015 
representing a regional prevalence of 2.1-6.7 % and this figure is expected to increase to 34.2 
million by 2040 [1]. The African region has the highest proportion of undiagnosed diabetes, 
with over 66.7% of people with diabetes being unaware that they have the disease. Recent data 
from the IDF estimate that 7 % of 3.8 million South Africans aged 21-79 years have diabetes 
[2, 3].  
 
 
Figure 1: Global burden of diabetes by IDF regions (image adapted from the International 
Diabetes Federation, Diabetic Atlas 2015) [1]. 
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1.2 Pathophysiology of Diabetes 
Diabetes mellitus is a heterogeneous group of disorders characterized by persistent 
hyperglycemia with disturbances in carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both [4]. The two most common forms of diabetes 
are Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) with the latter accounting for 90-95% 
of all diabetes cases affecting the general population while the former accounts for 5-10% and 
generally affects children [5, 6]. However, other rare forms of diabetes are Maturity Onset 
Diabetes of the Young (MODY), Gestational Diabetes Mellitus (GDM) and Idiopathic diabetes 
[4]. GDM develops during pregnancy causing dysregulation of carbohydrate and lipid 
metabolism due to acquired insulin resistance resulting in maternal hyperglycemia [7]. MODY 
is a monogenic form of diabetes that is usually first diagnosed in adolescence or early adulthood 
characterized by gene mutations that limit the ability of the pancreas to produce insulin [4]. 
Clinical symptoms associated with diabetes are due to chronic hyperglycemia and 
corresponding endocrine maladaptations. Glycosuria accompanied by polyuria is common in 
diabetic patients leading to dehydration that triggers compensatory polydipsia [8, 9]. Diabetes 
may be diagnosed by glycated hemoglobin (HbA1c) or blood glucose concentrations where the 
latter is either the Fasting Blood Glucose (FBG), Random Blood Glucose (RBG) or Impaired 
Glucose Tolerance (IGT) with a 75 g glucose challenge [10].  
According to American Diabetes Association (ADA) HbA1c is a marker of chronic glycemia 
reflecting average blood glucose levels over a 2 to 3-months with the cut-off point of ≥ 6.5% 
for confirming diabetes as an alternative to FPG  ≥ 6.0 mmol/l and RBG of >11.0 mmol/l. 
Glucose intolerance is defined by failure of blood glucose levels to return to baseline in 2-hours 
post 75g oral glucose challenge [11, 12]. Patients must have fasted for more than 8 hours before 
interpretation of OGTT. 
The normal blood glucose concentrations range from 3.1 mmol/l – 7.8 mmol/l depending on 
the fed or fasted state of the person [10, 13]. 
 A minimum concentration of 2.2-3.3 mmol/l is required to provide adequate fuel for the central 
nervous system. Glucose is its primary energy source and its uptake by the brain is independent 
of insulin [14]. The glomerulus filters large volumes of urine from the blood stream and glucose 
is usually reabsorbed in circulation in a multiple step process via the Sodium Glucose co-
Transporter 2 (SGLT2) in the proximal convoluted tubule and Glucose Transporter 2 (GLUT-
2) transporters at the basolateral membrane back into the blood [15, 16]. When blood glucose 
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concentrations exceed reabsorptive capacity of the kidney (10 mmol/l), glucose appears in 
urine resulting in loss of calories and water [17, 18].  
Diabetes end-points such as ketoacidosis, neuropathy, retinopathy, nephropathy and 
cardiovascular diseases contribute to increased morbidity and mortality not only in the 
developed but also more devastatingly so in developing countries [19]. These end-points are 
universal to all types of diabetes including T2D, which is the most common in adults but is 
now increasingly being encountered in adolescents [19]. 
 
1.3 Type 1 diabetes 
Type 1 diabetes (juvenile or insulin-dependent diabetes) is caused by autoimmune destruction 
of the insulin-producing pancreatic β-cells, following insult by environmental factors, such as 
viruses or toxins and chemicals [20].  Streptozotocin (STZ) is a glucosamine nitrosourea 
compound derived from Streptomyces achromogenes that was used clinically as a 
chemotherapeutic agent in the treatment of pancreatic β-cells carcinoma but now used to induce 
experimental diabetes [21]. It causes permanent diabetes in animal models by damaging 
pancreatic β-cells through generation of superoxide anions that act on the mitochondria causing 
an increase in the activity of the enzyme xanthine oxidase causing total or partial destruction 
of the pancreatic β-cells [22, 23].  
The administration of STZ at 60 mg/kg or 45 mg/kg doses has been shown to cause total or 
partial pancreatic β-cells destruction, respectively [24]. T1D is also closely associated with 
histocompatibility antigens (Human Leukocyte Antigen (HLA)-DR3 or HLA-DR4) and the 
presence of circulating insulin antibodies, including Glutamic Acid Decarboxylase (GAD), 
Islet Cell Antibody (ICA), and islet cell antibody 512 or IA2 (a tyrosine phosphatase antibody) 
[25, 26]. It was recently documented that antibodies to GAD are sensitive markers for diabetes 
development but may also be present in genetically susceptible individuals who are unlikely to 
develop the disease [27]. 
It has also been shown that T-cells, macrophages and cytokines are implicated in the 
pathological development of T1D with CD4+ T cells sufficient to induce insulitis while CD8+ 
T cells contribute to the severity of the damaged β-cells [28, 29]. Failure of the 
immunoregulatory system causes auto-reactive T-cells to activate Type 1 T helper (Th1 cells) 
that promote inflammatory immune responses and suppresses Type 2 T helper (Th2), which is 
a subset of the CD4+ T cells responsible for humoral immunity [30].  
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Th1 causes the secretion of pro-inflammatory mediators interleukin 2 (IL-2), interferon gamma 
(IFN-γ), tumor necrosis factor beta (TNF-β) and tumor necrosis factor alpha (TNF-α) [29, 31] 
(Fig. 2). Clinical onset of T1D is preceded by an extensive asymptomatic period during which 
β-cells are destroyed because the capacity of normal pancreatic β-cells to secrete insulin far 
exceeds the normal amounts needed to control carbohydrate, fat and protein metabolism [20].  
Patients with insulin deficiency are unable to utilize glucose in peripheral tissues such as 
skeletal muscles and the adipocytes, therefore resulting in increased secretion of counter-
regulatory hormones such as glucagon, adrenaline (epinephrine), cortisol, and growth hormone 
[32]. The destruction of β-cells may occur rapidly, but is more likely to take place over a period 
of weeks, months, or even years [33]. Deficiency of insulin leads to uncontrolled lipolysis and 
elevated levels of free fatty acids (FFA) in the plasma, which suppresses glucose metabolism 
in peripheral tissues such as skeletal muscles [29].  
Impairment of glucose utilization and insulin deficiency also decreases the transcription of a 
number of genes necessary for target tissues to respond normally to insulin e.g. glucokinase 
(liver) and glucose transporter 4 (GLUT4) (adipose tissue) [29, 34]. Some patients, particularly 
children and adolescents have a tendency to develop ketoacidosis as the first manifestation of 
the disease [4]. Initially only postprandial hyperglycemia is apparent but as insulin secretion 
gradually diminishes, progressive fasting hyperglycemia is encountered and eventually all T1D 
patients will require insulin therapy to maintain normoglycemia [4]. 
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Figure 2. Etiology of Type 1 Diabetes [35]. 
 
1.4 Type 2 diabetes 
T2D is one of the most common public health problems worldwide that is largely influenced 
by genetic predisposition and environmental factors (Fig. 3) [36]. It is a heterogeneous disorder 
characterized by impaired glucose tolerance, obesity, dyslipidemia, insulin resistance (IR), 
increased hepatic glucose production, pancreatic β-cell dysfunction and hyperglycemia [37]. 
Obesity is generally considered to be a strong risk factor for the development of T2D, and is 
defined by body mass index (BMI) of greater than or equal to 30 kg/m2 [38]. Visceral adiposity 
escalates the development of IR and T2D through excess adipose tissue that contributes to 
increased circulating FFA and reduced peripheral glucose utilization [39].  
Excess fatty acids also result in increased deposition of fat in the skeletal muscles and the liver, 
increased metabolites such as diacylglycerol that activate isoforms of protein kinase C (PKC) 
that impede cellular insulin signaling [40]. The detrimental effects of several adipokines such 
as TNFα, and IL-6 which are produced in excess by an increased adipose mass, and reduced 
production of adiponectin are further mechanisms through which obesity potentiates the 
development of T2D [41]. Although there is a strong genetic link in T2D onset there is no 
association with HLA types and circulating ICAs are absent [42].  
The pathophysiology of T2D is poorly understood, however in the early stages of the disorder 
there is no glucose intolerance, despite insulin resistance because the pancreatic β-cells 
compensate by increasing insulin output [43]. Insulin resistance and compensatory 
hyperinsulinemia progress and may lead to downregulation of insulin receptors on the target 
organs especially the skeletal muscles. Pancreatic β-cells lose their ability to secrete insulin 
over time, leading to increased loss of glucose control and further hyperglycemia [4, 44, 45].  
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Figure 3. Pathogenesis of Type 2 Diabetes characterized by impaired secretion and insulin    
resistance [29]; IGT (impaired glucose tolerance). 
 
1.4.2 Insulin Resistance (IR) 
 
IR is defined as diminished ability of insulin to exert its usual biological effects on target tissues 
especially skeletal muscles and adipose tissue [46]. It is a prominent feature of T2D and results 
from a composite of abnormalities including obesity, glucose intolerance, dyslipidemia and 
hypertension [47]. Although the precise molecular mechanism leading to IR in T2D have not 
been elucidated, it is believed to be primarily caused by metabolic abnormalities resulting from 
defects in glucose uptake due to defective regulation of GLUT-4 protein [48]. The defects in 
translocation of GLUT-4 protein is caused by reduced tyrosine phosphorylation of insulin 
receptor substrate-1 (IRS-1) [49, 50]. Phosphorylated IRS proteins serves as multisite docking 
proteins for various effector molecules possessing src homology 2 (SH2) domains, including 
phosphatidylinositol-3-kinase (PI3K) regulatory subunits, the tyrosine kinases as well as 
several smaller adapter molecules such as the growth factor receptor binding proteins (Fig. 4) 
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[48, 51, 52]. IRS proteins function as essential signaling intermediates downstream of activated 
cell surface insulin receptors and play a central role in maintaining basic insulin-mediated 
cellular functions including glycogen synthesis, protein synthesis, cell survival through glucose 
uptake, fatty acid synthesis and inhibit gluconeogenesis [53]. 
 IR occurs at multiple levels in cells, from the cell surface to the nucleus including insulin 
receptor desensitization. Inhibition of IRS-1 and insulin receptor substrate-2 (IRS-2) result in 
suppression of IRS protein and functionality, inhibition of PI3K cascades, and failure to restrain 
fork head box protein O1 (FOXO1) activated gene transcriptional profiling. [54, 55]. Insulin 
stimulates amino acid uptake into cells, inhibits protein degradation and promotes protein 
synthesis [56]. Its shortage in the diabetic state causes a profound increase in protein 
catabolism, rather than a decline in protein synthesis [57]. 
 
Figure 4. Insulin signaling pathways. The binding of insulin to its receptor leads to 
autophosphorylation on the insulin receptor (IR) subunit and the Tyr phosphorylation of 
IRS proteins and other downstream signaling molecules such as Shc. Activation of theses 
downstream effectors appears to be important for glucose transport, protein, glycogen, and 
lipid synthesis, whereas activation of Growth factor receptor-bound protein 2 (Grb2) dependent 
or independent of IRS-1 (but dependent of Shc) leads to activation of MAPK signaling 
pathways that control cell proliferation and growth [52]. 
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1.5 Gestational diabetes 
Gestational diabetes is defined as glucose intolerance with onset or first recognition during 
pregnancy [58]. The onset of diabetes during pregnancy and its duration affect the prognosis 
for a good obstetric and perinatal outcome [59, 60]. Although early diagnosis and management 
of GDM are still controversial, they result in beneficial effects on maternal and neonatal 
outcomes, and if not managed correctly may lead to diabetes postpartum [61]. GDM is 
diagnosed by OGTT between 24 and 28 weeks of pregnancy [62, 63]. Hyperglycemia develops 
during pregnancy because of secretion of placental hormones, which cause insulin resistance 
by preserving pregnancy and blocking actions of insulin (counter-insulin) impairing the 
mother’s insulin secretion capacity [64]. It occurs in up to 7% of pregnant mothers and 
increases risk of preeclampsia [65]. Initial management includes dietary modification, exercise 
and blood glucose monitoring [66].  
The main goal of treatment is good glycemic control during pregnancy to avoid macrosomia 
with its attendant risks and if hyperglycemia persists, insulin therapy is the mainstay of 
treatment according to standard treatment guidelines [67]. However, insulin has several 
drawbacks including multiple daily injections, the risk of hypoglycemia and maternal weight 
gain. Although insulin remains first-line treatment for GDM, safe and effective oral therapy 
would be more acceptable even highly desired for women with GDM. Langer et al. [68] and 
Rowan et al. [69] have shown that some oral hypoglycemic agents for treating GDM have 
gained popularity and can be good alternatives to insulin. Glyburide and metformin could be 
used as oral treatments for GDM regarding glucose control and treatment failure. Their 
incorporation in the management of GDM could allow higher efficacy rate with a significantly 
reduced need for insulin that should be reserved for patients who fail to respond to both oral 
treatments or who experienced adverse effects because of both [70].  
 
Despite the significant gains shown with glyburide efficacy in GDM management, it was 
regarded inferior to insulin because of an elevated risk for neonatal intensive care unit 
admission, respiratory distress, neonatal hypoglycemia, birth injury, and macrosomia [71-74]. 
However, metformin inhibits hepatic gluconeogenesis and glucose absorption and stimulates 
glucose uptake in peripheral tissues, with the effect of reducing maternal weight gain, and 
neonatal hypoglycemia [75]. Obesity is always associated in high risk for metabolic diseases, 
so less weight gain could lead to reduced incidence of other complications. More observational 
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studies are needed to confirm that metformin and glyburide can be used as add-on therapy in 
GDM and standard treatment guidelines could be revised to incorporate both drugs. 
According to ADA, targets of blood glucose levels during pregnancy are ≤ 5.8 mmol/l for 
fasting plasma glucose and ≤ 6.7 mmol/l or less 2 hours after meals [76]. After giving birth, 
blood glucose levels in the women with GDM are supposed to return to normal. However, 
many women who have had GDM may develop T2D later in life. Therefore, all women who 
had GDM should be recommended to maintain their ideal body weight and to exercise regularly 
to reduce their risk for T2D [77]. Metformin could be used in women with GDM with 
observations of comparative glycemic control and neonatal outcomes, especially for patients 
with mild GDM. However, the risk of preterm birth cannot be ignored. Clinicians should weigh 
the benefits versus risks of metformin in management of GDM according to the specific 
condition of patients. Further studies with larger sample sizes shall be designed to assess 
maternal and neonatal complications and to evaluate long-term follow-up of children for the 
safety of metformin as a universal treatment for GDM patients. 
1.6 Maturity onset diabetes of the young  
MODY is a rare form of diabetes that is associated with a strong family history that suggests 
an autosomal dominant transmission [78]. This is characterized by a slow onset of symptoms, 
the absence of obesity, lack of ketosis, and no evidence of β-cells autoimmunity. There are six 
different variants of MODY, caused by mutations in genes encoding islet enriched transcription 
factors or glucokinase [79]. MODY 1, MODY 3 and MODY 5 are caused by mutations in the 
hepatocyte nuclear transcription (HNF) 4α, HNF-1α and HNF-1β factors respectively [80]. 
These transcription factors are expressed in the liver but also in other tissues including the 
pancreatic islets and the kidney.  
They affect islet development or the expression of genes important in glucose-stimulated 
insulin secretion and the maintenance of β-cells mass [80]. Individuals with MODY 2 have 
mutations in the glucokinase gene that plays a key role in glucose metabolism and insulin 
secretion [81]. MODY 2 patients have mild to moderate, stable hyperglycemia that is present 
from birth and generally stable throughout life and does not respond to oral hypoglycemic 
agents [82].  
MODY 4 is a rare variant form caused by mutations in insulin promoter factor (IPF) 1, which 
is a transcription factor that regulates pancreatic development and insulin gene transcription 
together with other genes involved in glucose metabolism [83]. Patients with MODY may 
present with moderate to severe symptoms with or without ketosis. Unlike T1D, the disease is 
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generally mild and controlled easily with diet, hypoglycemic oral agents, or low doses of 
insulin (<40 units) [83]. 
 
1.7 Idiopathic diabetes 
Some forms of TID have no known etiologies, however, patients may have permanent 
insulinopenia and are prone to ketoacidosis, although no evidence of autoimmunity [12]. Even 
though only a minority of patients with T1D fall into this category, of those who do, most are 
of African or Asian ancestry  [12]. Individuals with this form of diabetes experience   episodes 
of ketoacidosis and exhibit varying degrees of insulin deficiency between episodes. This form 
of diabetes is strongly inherited, lacks immunological evidence for β-cells autoimmunity, and 
is not HLA associated [84].  
 
1.8 Diabetic complications 
Diabetes is associated with acute metabolic and long-term vascular complications [85]. If 
hyperglycemia is not controlled, it leads to serious metabolic complications [86]. With such 
metabolic complications there is a reduction in the action of circulating insulin together with 
an elevation of counter-regulatory hormones such as glucagon, catecholamines, cortisol and 
growth hormone [9].  
The end-result of these acute metabolic complications is ketonemia, metabolic acidosis, 
glycosuria, osmotic diuresis with loss of water, sodium, potassium and other electrolytes [87]. 
The long-term vascular complications of diabetes that occur as a result of hyperglycemia are 
grouped into macrovascular such as coronary artery disease, peripheral arterial disease and 
stroke, and microvascular complications such as diabetic nephropathy, neuropathy, retinopathy 
and cardiomyopathy [88]. 
 
1.8.1 Acute Metabolic Complications in Diabetes 
The two most common life-threatening complications of uncontrolled diabetes mellitus include 
diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS). DKA usually 
occurs in patients with T1D but HHS is mostly diagnosed in patients with T2D and they both 
require prompt recognition and aggressive therapy to optimize clinical outcomes [89].  
Although there are important differences in their pathogenesis, the basic underlying mechanism 
for both disorders is a reduction in the effective concentrations of circulating insulin leading to 
hyperglycemia and severe dehydration [90]. 
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These hyperglycemic emergencies continue to be important causes of morbidity and mortality 
in patients with diabetes [86].  
 
1.8.1.1 Diabetic Ketoacidosis 
DKA is an acute but major life-threatening complication of diabetes that mainly occurs in 
patients with TID even though uniquely frequent among some patients with T2D [91]. It is 
defined by blood glucose concentrations >11.0 mM, venous blood pH<7.3, bicarbonate<15 
mM, glycosuria, ketonemia and ketonuria [92]. DKA is a consequence of absolute or relative 
lack of insulin with a concomitant rise in plasma levels of insulin counter-regulatory hormones 
such as catecholamines, glucagon, cortisol and growth hormone leading to hyperglycemia and 
ketosis (Fig. 5) [91]. The combination of insulin deficiency and hyperglycemia reduces the 
hepatic level of fructose-2, 6-phosphate, which alters the activity of phosphofructokinase and 
fructose-1, 6-bisphosphatase and ultimately increase glucose synthesis with a subsequent 
decrease in glycolysis [93].  
Insulin deficiency also reduces levels of the GLUT4, which impairs glucose uptake into 
skeletal muscles and adipose tissues thus reducing intracellular glucose metabolism [94]. 
Ketosis results from a marked increase in FFA released from adipocytes, with a resulting shift 
towards ketone body synthesis rather than utilization in the liver, which leads to accumulation 
of acetoacetate and β-hydroxybutyrate and eventually induction of anion gap metabolic 
acidosis. However, hyperglycemia develops as a result of increased gluconeogenesis, 
accelerated glycogenolysis and impaired glucose utilization by peripheral tissues [93, 95, 96].  
The clinical presentation of DKA usually develops rapidly, i.e. over a period of < 24 hours 
presenting with polyuria, polydipsia and weight loss [91, 97]. With appropriate therapy the 
mortality in DKA is low (<5%) and is related more to the underlying or precipitating events, 
such as infections or myocardial infarction [98]. The major non-metabolic complication of 
DKA therapy is cerebral edema, which most often develops in children [99]. 
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Figure 5. Pathophysiology of diabetic ketoacidosis (DKA). Insulin insufficiency promotes 
gluconeogenesis in the liver and ketogenesis in the skeletal muscles. Increased production of 
insulin counter-regulatory hormones promotes lipolysis and proteolysis in the adipose tissue 
and the skeletal muscles courtesy. Malnutrition, oxidative stress as well as pro-inflammatory 
cytokines further exacerbate β-cells destruction, lipolysis and proteolysis. Hyperglycemia and 
increased production of ketone bodies lead to tissue hypoxia, osmotic diuresis, dehydration and 
hyperlactacidemia [98]. 
 
1.8.1.2 Hyperglycemic hyperosmolar state 
HHS is characterized by a relative deficiency of insulin concentrations to maintain 
normoglycemia but adequate levels to prevent lipolysis and ketogenesis as determined by 
residual C-peptide [96, 100]. Insulin deficiency leads to hepatic glucose production (through 
glycogenolysis and gluconeogenesis) and impairs glucose utilization in the skeletal muscles. 
Hyperglycemia induces osmotic diuresis that leads to intravascular volume depletion, which is 
exacerbated by inadequate fluid replacement.  
Although the fundamental difference between HHS and DKA is small, HHS is characterized 
by a greater severity of plasma glucose elevation (>33.3 mmol/L), marked increase of plasma 
osmolality (>320 mOsm/kg), absence of or mild ketosis, and altered mental status [91, 97]. It 
is associated with glycosuria, leading to osmotic diuresis, loss of water, sodium, potassium, 
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and other electrolytes. General treatment of DKA and HHS requires frequent monitoring of 
patients, correction of hypovolemia and hyperglycemia, replacement of electrolyte losses, and 
attention to precipitating factors [90].  
Treatment of DKA and HHS is initiated with intravenous (IV) fluids, normal saline (0.9% 
NaCl) at the rate of 15-20 mL/kg body weight during first hour unless the patient has cardiac 
dysfunction and then followed by 0.45% normal saline at a rate of 4-14 [101]. Once serum 
glucose reaches 11.1 mmol/l, IV fluids should be changed to 5% dextrose with 0.45% NaCl at 
150-250 mL/hr.  
Then continuous insulin infusion should be administered at bolus dose of  0.1 unit/kg IV and 
maintenance dose of  0.1 unit/kg/hr IV. Adequate renal function should be established (urine 
output ~50 mL/hr). If K is <3.3 mEq/L, insulin can be stopped and 20-40 mEq/hr of K should 
be given until K >3.3 mEq/L. If  K is  >5.5mEq/L, it should not be given but, if  K is  between 
>3.3 and <5.3 mEq/L, K at  20-30 mEq should be given  in each liter IV fluid to maintain K 
between 4-5 mEq/L [101]. 
 
1.8.2. Metabolic causes of complications of diabetes  
 
Although chronic hyperglycemia is an important etiologic factor leading to complications of 
diabetes, the mechanisms  by which it leads to such diverse cellular and organ dysfunctions are 
unknown [93]. Increased glucose levels lead to accumulation of glycolytic metabolites and 
glucose modified proteins that are otherwise referred to as glucotoxins [102]. In general, the 
adverse-effects of hyperglycemia can cause vascular dysfunctions either by generating toxic 
and reactive metabolites or by altering intracellular signaling pathways [102]. Several 
molecular pathways have been proposed in an effort to explain the pathological developments 
of these complications and include the hexosamine pathway, polyol pathway, PKC activation, 
enhanced oxidative pathways, and formation of Advanced glycated end-products (AGEs) (Fig. 
6) [103]. 
1.8.2.1 Advanced Glycation End-products 
AGEs are formed by increased intracellular glucose via the non-enzymatic glycosylation of 
intra and extracellular proteins, which may change protein conformation and permanently 
impair their functions [104]. Intracellular production of AGE precursors appear to damage 
cells by mechanisms such as modification of intracellular proteins including those involved 
in the regulation of gene transcription [105, 106]. AGE precursors diffuse out of the cell, 
modify circulating proteins in the blood such as albumin and as a result circulating proteins 
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bind to AGE receptors and activate them. This causes the production of inflammatory cytokines 
and growth factors such as TNF-α and IL-1, which in turn induce a degenerative and 
proliferative cascade in mesenchymal and endothelial cells (Fig. 6) [107, 108]. AGEs can also 
alter cellular functions by binding to their receptors, such as the receptor for advanced glycation 
end-products (RAGE) or other receptors, including the macrophage scavenger receptor, p60, 
p90 and galectin-3 [109, 110].  
RAGE is a transmembrane protein that belongs to the immunoglobulin family expressed in 
several cells and tissues, including endothelial cells and upon binding to AGEs [111] it initiates 
multiple cascades of cellular signaling pathways, including p44/42 MAPK and PKCs, and 
further disrupts cellular homeostasis [112, 113]. AGEs can be detected in the serum and 
glomerular tissues, therefore increased levels in these locations are strong indicators of tissue 
damage. The serum level of AGEs correlates with the level of glycemia and these products 
accumulate as glomerular filtration rate declines [85, 114].  AGEs block nitric oxide activity in 
the endothelium and cause the production of ROS, and early glycation and oxidation processes 
result in the formation of Schiff bases and Amadori products [115]. 
1.8.2.2 Oxidative stress 
Hyperglycemia increases oxidative stress through several pathways. A major mechanism 
appears to be the over production of the superoxide anion O2•− by the mitochondrial electron 
transport chain [116]. Physiological generation of species O2•− (particularly the superoxide 
radical) occurs during normal electron shuttling by cytochromes within the electron transport 
chain [116]. Hyperglycemia leads to an increased production of electron donors (NADH and 
FADH2) by the tricarboxylic cycle that as a result generate a high mitochondrial membrane 
potential by pumping protons across the mitochondrial inner membrane [117]. Therefore, the 
voltage gradient across the mitochondrial membrane will increase until a critical threshold is 
reached, and electron transport inside complex III is blocked [118]. This increases the half-life 
of free radical intermediates of coenzyme Q (ubiquinone) which reduces O2 to superoxide, and 
markedly increases the production of superoxide [119, 120]. ROS generation from various 
organs/tissues has been associated with decline in the pancreatic β-cells function as observed 
in T2D (Fig. 6) [121]. 
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1.8.2.3 The Polyol Pathway 
Intracellular glucose is predominantly metabolized by phosphorylation and subsequent 
glycolysis. However, when blood glucose concentrations increase it is converted to sorbitol by 
aldose reductase [122], which reduces toxic aldehydes in the cell to inactive alcohols, but when 
the glucose concentrations in the cells increases, it also reduces that glucose to sorbitol 
reductase through the cofactor Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 
[122]. NADPH is an essential cofactor for regenerating critical intracellular antioxidants, and 
eventually reduced to glutathione [123]. Sorbitol is then oxidized to fructose by sorbitol 
dehydrogenase, which uses Nicotinamide Adenine Dinucleotide (NAD+) as a cofactor. As 
glutathione levels decrease, cellular antioxidant capacity becomes compromised, resulting in 
elevated levels of ROS that can attack macromolecules and induce oxidative damage [123, 
124]. Sorbitol is not easily metabolized and therefore will accumulate intracellularly. Hence 
increased sorbitol concentrations alters redox potential, increases cellular osmolality, generates 
ROS and eventually leads to other types of cellular dysfunction [122, 125, 126]. 
 
1.8.2.4 Protein Kinase C Pathway 
 Hyperglycemia increases the synthesis of DAG mainly from phosphoinositol diphosphate 
(PIP2), which is a critical activating cofactor for the classic isoforms of protein kinase β 1/2, γ, 
and α [127]. DAG levels are elevated chronically due to an increase in the glycolytic 
intermediate dihydroxyacetone phosphate that is reduced to glycerol-3-phosphate and 
subsequently increases the synthesis of DAG [128, 129]. When PKC is activated by increased 
intracellular glucose, it has a variety of effects on gene transcription for fibronectin, type IV 
collagen, contractile proteins, and extracellular matrix proteins in endothelial cells and neurons 
[129]. Endothelial dysfunction is accompanied by a decreased production of prostacyclin, 
Nitric Oxide (NO) that is responsible for maintaining blood vessel integrity and increasing 
endothelin-1, vascular endothelial growth factor and cyclooxygenase dependent 
vasoconstrictors [130]. Some studies showed that inhibition of PKC prevented early changes 
in the diabetic retina and kidney thus ameliorating the detrimental effects mediated by the 
activation and action of PKC [131, 132] (Fig. 6).  
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1.8.2.5 Hexosamine pathway     
Increased intracellular glucose is usually metabolized in glycolysis through glucose-6-
phosphate (G-6-P) and fructose-6-phosphate (G-6-P). However, F-6-P can also be diverted into 
a signaling pathway where glutamine: fructose-6 phosphate aminotransferase (GFAT) converts 
the F-6-P to glucosamine-6-phosphate (G-6-P) and finally to uridine diphosphate (UDP) N-
acetyl glucosamine [103, 133]. Inhibition of GFAT, the rate-limiting enzyme in the conversion 
of glucose to glucosamine blocks the increase of transforming growth factor-1 (TGF-1) and 
plasminogen activator inhibitor-1 (PAI-1) transcription [134, 135]. N-acetyl glucosamine 
results in pathologic changes which increases modification of the transcription factor Sp1 
leading to an increase in the expression of TGF-1 and PAI-1 both of which are harmful for 
blood vessels in diabetic individuals [136, 137] (Fig. 6). 
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Figure 6. Mechanisms by which hyperglycemia induces diabetic vascular complications. ET-
1 (Endothelin-1); NADPH (Nicotinamide Adenine Dinucleotide Phosphate); PDGF (Platelet-
Derived Growth Factor);TGF-β (Transforming Growth Factor-β); VEGF Vascular Endothelial 
Growth Factor [136]. 
 
1.8.3 Long-term Complications of Diabetes 
 
Diabetic patients develop end-point complications such as cardiovascular diseases, stroke, 
atherosclerosis, nephropathy, neuropathy, retinopathy and cardiomyopathy [85]. These 
complications can be categorized into two major groups namely microvascular and 
macrovascular complications. 
 
1.8.3.1 Microvascular Complications of Diabetes  
1.8.3.1.1 Diabetic Retinopathy 
Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes. 
Globally, diabetic retinopathy affects 2 million people and the prevalence is approximately 
35% of all cause cases of blindness [138]. In industrialized countries, DR is the leading cause 
of blindness in people aged 15 - 64 years [139]. It is defined as a microvascular complication 
that affects the peripheral retina, macula, or both leading to visual impairment and blindness in 
people with diabetes [85]. Biochemical alterations such as oxidative stress, activation of PKC 
and formation of AGEs have been shown as responses of the retina to hyperglycemia [104, 
140]. DR is generally classified as either background (nonproliferative retinopathy) or 
proliferative whereby background retinopathy develops first and causes increased capillary 
permeability, microaneurysms, hemorrhages, exudates, macular ischemia, and macular edema 
[141]. Proliferative retinopathy is characterized by the formation of new blood vessels on the 
surface of the retina and can lead to vitreous hemorrhage [142]. If proliferation continues, 
blindness can occur from vitreous hemorrhage and traction retinal detachment intervention is 
made [139]. These changes cause glaucoma and cataracts and if not treated could lead to total 
blindness. 
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1.8.3.1.2 Diabetic nephropathy 
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) which is 
characterized by glomerular hemodynamic abnormalities that result in glomerular 
hyperfiltration, leading to glomerular damage as evidenced by microalbuminuria (albumin 
excretion of 30–299 mg of albumin/g of creatinine) [143]. As glomerular function continues to 
decline, overt proteinuria (presence of proteins of greater than 0.5g/24 h) increases, glomerular 
filtration rate (GFR) declines and ESRD escalates [144]. DN is also characterized by the 
elevation of blood pressure and progressive renal insufficiency due to glomerular lesions and 
loss of GFR in the absence of albuminuria [143]. Dyslipidemia with increased low-density 
lipoprotein (LDL) cholesterol and triglycerides are independently associated with diabetic 
kidney disease [145, 146]. The pathophysiological mechanisms underlying DN involve 
generation of ROS, AGEs, and activation of intracellular signaling moieties such PKC [147, 
148]. Glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibition have long 
been mainstays of therapy in patients with Diabetic kidney disease (DKD) [149]. Clinically, 
Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin Receptor Blockers 
(ARBs) have been a cornerstone for management of DKD because of their effectiveness in 
delaying the progression of diabetic nephropathy [150, 151]. Conversely, poor blood pressure 
control can accelerate the progression of diabetic nephropathy [152].  
Multiple large-scale clinical trials have demonstrated that improved glycemic control in 
patients with T1D and T2D have reduced microalbuminuria, macroalbuminuria and 
progression to DKD and ESRD [153-155]. ACEIs and ARBs have been extensively studied, 
and are considered superior to other antihypertensive drug categories in the treatment of DN 
because of their capacity to reduce both intraglomerular pressure and proteinuria by 
preferentially dilating the efferent arteriole [152]. Furthermore, it has been reported that 
renoprotective effects of treatment with ACE inhibitors and ARBs, which appear to be 
present regardless of their blood pressure-lowering effects, possibly because of decreasing 
intraglomerular pressure. Which further decreases the risk of progression of kidney disease 
independent of the blood pressure-lowering effects [152, 156]. 
 
1.8.3.1.3 Diabetic neuropathy 
 Diabetes causes both acute and chronic neuropathies characterized by signs and symptoms of 
peripheral neural impairment in patients with diabetes distinct from other causes of neural 
damage [157]. Diabetic neuropathy is thought to be caused by both direct hyperglycemia-
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induced damage to the nerve parenchyma and neuronal ischemia resulting from 
hyperglycemia-induced decreases in neurovascular flow [158]. The risk of developing diabetic 
neuropathy is directly proportional to both the duration and magnitude of hyperglycemia [85]. 
The precise nature of injury to the peripheral nerves from hyperglycemia is not known but is 
likely related to mechanisms such as polyol accumulation, injury from AGEs, and oxidative 
stress [125, 159]. The most common chronic neuropathic complication of diabetes is distal 
symmetric polyneuropathy (DSP) [160]. It frequently presents with loss of peripheral sensation 
which, when coupled with impaired microvascular and macrovascular function in the 
periphery, can contribute to non-healing ulcers the leading cause of nontraumatic amputation 
[161]. Although up to 50% of patients do not have symptoms of neuropathy, DSP is manifested 
clinically by paresthesia, dysesthesia, pain, impaired reflexes, and/or decreased vibratory 
sensation [160, 161]. 
DSP can either be typical or atypical, whereby typical DSP is chronic, distal, symmetric, 
sensory dominant and often painful. Any variations that may be proximal or asymmetric 
suggest an atypical neuropathy [162].  An estimated 20% of patients with DSP experience 
severe pain and it is the leading cause of foot ulceration and limb amputations [163, 164]. 
Diabetic patients also tend to develop autonomic neuropathy, including cardiovascular 
autonomic dysfunction, which is characterized by abnormal heart rate and vascular control 
[165]. Diabetic cardiomyopathy has been associated with cardiac autonomic dysfunction and 
patients with diabetic cardiomyopathy have diastolic filling and relaxation abnormalities, 
which are then commonly followed by systolic dysfunction and heart failure [166]. 
 
1.8.3.2 Macrovascular complications of diabetes 
In macrovascular complications, the injurious effects of hyperglycemia lead to chronic 
inflammation and injury to the arterial walls in the peripheral or coronary vascular system 
therefore resulting in atherosclerosis, which in turn narrows the arterial walls [145]. Oxidized 
lipids from LDL particles then respond to endothelial injury and inflammation by accumulating 
in the endothelial wall of the arteries [167, 168]. Foam cells eventually form as a result of 
immune response activation whereby the stimulation of macrophage proliferation and T-
lymphocyte attraction occurs and thereby inducing collagen accumulation in the arterial walls 
[169]. The result of this pathogenesis is the formation of lipid-rich atherosclerotic lesions with 
fibrous caps. This explains why diabetic patients are at increased risk of developing 
20 
 
cardiovascular diseases such as myocardial infarction (MI), making diabetes an independent 
risk factor for ischemic diseases, coronary artery disease, stroke and death [170]. 
 
1.8.3.2.1 Diabetic cardiomyopathy 
 
Diabetic cardiomyopathy (DCM) refers to diabetes-associated structural and functional 
myocardial dysfunction not related to other confounding traditional factors such as coronary 
artery disease (CAD), hypertension, congenital heart diseases or valvular heart diseases [171, 
172]. It affects approximately 12% of diabetic patients globally [173], leading to overt heart 
failure and death. DCM is characterized by myocardium structural abnormalities leading to left 
ventricular hypertrophy (LVH), diastolic and systolic dysfunction or a combination of both 
[174]. These events follow metabolic alterations induced by hyperglycemia, insulin resistance 
and dyslipidemia, which alter signal transduction pathways that regulate cardiac function [175]. 
One of the principle abnormalities is the excess generation of AGEs that deactivate NO and 
impair coronary artery vasodilation [176].  
Sustained hyperglycemia causes excess formation of mitochondrial ROS that results in cardiac 
glucotoxicity, mitochondrial failure and apoptosis, fibrosis and eventually contractile 
dysfunction [177]. Although the increase in HF and cardiovascular mortality are mainly due to 
accelerated atherosclerosis, compelling epidemiological and clinical data indicate that diabetes 
mellitus increases the risk for cardiac dysfunction and heart failure independently of other risk 
factors such as CAD and hypertension [178]. In this regard, an early and specific detection of 
DCM could be worthwhile for appropriate therapeutic interventions.  
 
1.9 Treatment of Type 2 Diabetes: The current Antidiabetic Agents 
Currently available therapeutic agents for diabetes include insulin and various oral anti-diabetic 
agents such as sulfonylureas, biguanides, α-glucosidase inhibitors, and glinides used as 
monotherapy or in combination to achieve better glycemic control (Table 1) [179]. 
 
Table 1: Drugs clinically used for treatment of T2D [180]. 
 
Class Example  Mechanism of 
action  
Side effects 
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Biquanides Metformin Lowers blood glucose 
concentrations by decreasing 
hepatic gluconeogenesis and 
increasing glucose uptake by 
skeletal muscles through 
activation of AMPK. 
Gastrointestin
al intolerance 
(diarrhea and 
other GI 
disturbances 
such as nausea, 
abdominal 
discomfort, 
metallic taste, 
and anorexia. 
Nonsulfonylu
reas 
secretagogues 
(Meglitinides) 
Repaglinide, 
Nateglinide. 
Blocks ATP-dependent 
potassium channels, stimulates 
insulin release from pancreatic 
β-cells. 
Hypoglycemia, 
associated with 
rare 
hepatotoxicity 
and weight 
gain. 
Sulfonylurea
s 
Glimepiride, 
Glipizide  
Chlorpropamide, 
Glyburide, 
Tolazamide, 
Tolbutamide. 
       
  
 
Stimulate the release of insulin 
from β-cells through 
interaction with ATP sensitive 
K channel and enhance β-cells 
sensitivity to glucose.  
 
Weight gain, 
hypoglycemia. 
α-
Glucosidase 
Inhibitors 
Acarbose, 
miglitol. 
Inhibits enzymes that break 
down carbohydrates into 
glucose and subsequent delay 
in glucose absorption. 
Flatulence, 
diarrhea, and 
abdominal 
pain. 
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Thiazolidine
diones  
Pioglitazone, 
Rosiglitazone. 
Bind to and activate a nuclear 
receptor  
Peroxisome proliferator-
activated receptor gamma 
(PPAR-γ), increase glucose 
transport into adipose, skeletal 
muscles and hepatocytes. 
Stimulation activates GLUT4 
gene transcription. 
 
Hepatotoxicity
, risk of 
myocardial 
infarction and 
weight gain. 
Amylin-
Receptor 
Agonists 
Pramlintide, 
Acetate. 
 Suppresses glucagon release, 
delays gastric emptying. 
Hypoglycemia 
and 
gastrointestina
l symptoms 
including 
nausea, 
vomiting, and 
anorexia. 
SGLT2 
inhibitors 
Dapagliflozin, 
canagliflozin, 
empagliflozin. 
Decrease renal glucose 
reabsorption and thereby 
enhancing urinary glucose 
excretion and subsequent. 
reductions in plasma glucose 
and glycosylated hemoglobin 
concentration. 
Urinary and 
genital tract 
infections 
more common 
with SGLT2 
inhibitors, 
hypotension. 
Dopamine 
D2-R 
antagonist 
Bromocriptine  Mechanism of action 
unknown. 
Hypotension, 
Hypoglycemia
. 
Insulin Rapid-acting 
(aspart, glulisine, 
lispro) Long-
acting 
Binds to insulin receptor, 
stimulate glucose transport 
across cell membrane by ATP 
dependent translocation of 
GLUT4 to the plasma 
Hypoglycemia
, weight gain 
and 
hypersensitivit
y reactions. 
23 
 
(glargine,detemir
) 
Intermediate-
Acting Insulin 
(Neutral 
Protamine 
Hagedorn 
(NPH). 
membrane. PIP3 and tyrosine 
phosphorylated guanine 
nucleotide exchange proteins 
facilitates GLUT4 
translocation from cytosol to 
plasma membranes. 
 
 
 
 
 
1.10 Pharmacotherapy with metformin 
 Biguanides have mostly been prescribed to patients whose hyperglycemia is due to ineffective 
insulin action (insulin resistance) [181]. Newly diagnosed T2D patients are currently treated 
with metformin as a first-line drug that has been shown to be associated with clinical benefits 
such as reduced insulin resistance, decreased hepatic glucose output, improved glycemic 
control and dyslipidemia. In addition, there is also reduction in weight gain and reduced risk 
of cardiovascular morbidity and mortality [182].  
Metformin is an insulin-sparing agent and does not increase weight or provoke hypoglycemia, 
it offers obvious advantages over insulin or sulfonylureas in treating hyperglycemia in T2D 
[183]. In the past 3 decades, metformin has been recommended as the first-line therapy for 
T2D by the American Diabetes Association (ADA), the European Association for the Study of 
Diabetes (EASD) and the American Association of Clinical Endocrinologists (AACE) 
treatment guidelines, respectively [184, 185].  
The United Kingdom Prospective Diabetes Study (UKPDS) reported that metformin therapy 
decreases the risk of macrovascular and microvascular complications of diabetes, which is in 
contrast to the other therapies that only modify microvascular morbidity [186]. However, 
despite significant gains with metformin as monotherapy in T2D, a considerable number of 
patients fail to achieve optimum glycemic control and are either maintained on metformin with 
insulin or insulin secretagogues, or switched to insulin monotherapy.  
Biguanides are also indicated for use in combination with insulin secretagogs or 
thiazolidinediones for T2D where oral monotherapy is inadequate. Repeated insulin injections 
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make some patients less compliant and some of the patients become intolerant to metformin 
because of associated side-effects such as GI disturbances, vitamin B12 malabsorption and rare 
lactic acidosis [187]. Metformin is controversially contraindicated in patients who have 
developed end-point diabetes complications such as heart or renal failure due to perceived risk 
of lactic acidosis [188, 189]. Phenformin is a biguanide with similar actions to metformin but 
was withdrawn from the markets because of increased incidence of lactic acidosis [190]. 
Phenformin has powerful inhibitory effects on functioning of the mitochondrial respiratory 
chain and inhibits lactate oxidation thus increasing plasma lactate concentrations leading to 
lactic acidosis [189]. 
New agents such as carbohydrate absorption inhibitors, glucagon-like peptide 1 (GLP1) 
agonists (analogs) or SGLT-1 and SGLT-2 antagonists despite their significant effects in 
controlling glycemia are not devoid of unwanted side-effects [191]. Recent reports indicated 
that the use of SGLT-2 inhibitors is associated with risk of DKA by increasing FFA and 
possibly reducing ketones clearance [192]. Other side-effects include an increase in incidence 
of genital tract infections (GTIs) and in some studies a numerical excess of urinary tract 
infections (UTIs) and bone fractures has been reported [193, 194].  
 
1.10.1 Metformin-associated lactic acidosis  
 
Although metformin is a drug of choice for the treatment of T2D, it is contraindicated in some 
patients due to the risk of lactic acidosis [195]. Metformin-associated lactic acidosis (MALA) 
is an extremely rare condition although cases continue to be reported and are associated with 
mortality rates of 30 to 50% [196]. Lactic acidosis is a life-threatening condition characterized 
by low blood pH (< 7.35) and elevated arterial lactate (> 5.0 mmol/L) levels [197]. It can occur 
in patients with predisposing factors such as renal insufficiency, hepatic disease, congestive 
heart failure and sepsis [198]. Lactic acidosis occurs during conditions of excessive lactate 
production and/or impaired hepatic lactate clearance. It is divided into two categories namely 
type A lactic acidosis which  results from the accumulation of lactate through glycolysis in the 
absence of oxygen and type B lactic acidosis which is known to be associated with metformin 
[195].  
Metformin has been shown in in-vitro studies to reduce oxygen consumption and glucose 
production in isolated rat hepatocytes in a dose-depend manner, by inhibiting Respiratory 
Chain Complex 1 (RCC1) and mitochondrial glycerophosphate dehydrogenase that impairs 
conversion of cytosolic lactate to pyruvate leading to increased plasma lactate levels and 
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reduction in ATP production [197]. Metformin stimulates conversion of glucose to lactate in 
the intestinal mucosa, blocks mitochondrial oxidative metabolism, decreases hepatic 
gluconeogenesis from lactate, pyruvate and alanine resulting in anaerobic glycolysis and lactate 
accumulation [199]. 
 It would be expected that this inhibition causes oxidative stress, which may lead to conversion 
of pyruvate to lactate in the cytosol and hence increased lactate levels [198, 200]. Although 
metformin is controversially contraindicated in patients who have developed end-point 
diabetes complications such as heart failure and renal failure due to perceived risk of lactic 
acidosis, the FDA stipulated that metformin may be initiated in patients with an eGFR >45 
mL/min/1.73 m2, but renal function should be assessed at regular intervals (3–6 months) 
depending on risk of developing renal impairment [201].  
eGFR not serum creatinine should be used to estimate kidney function in patients with renal 
impairment because serum creatinine is dependent on several factors. Patients already initiated 
on metformin treatment can continue cautiously on such treatment but depending on benefits 
and risks if eGFR >30-45 mL/min/1.73 m2 and appropriate monitoring in patients is required 
[202, 203]. Therefore, it should be envisioned that in CKD stage 3 or 4 there is a further renal 
functional decline and consequently metformin may accumulate leading to metabolic/lactic 
acidosis [204].  
The FDA recommended that metformin could be associated with reduced readmissions and 
mortality in patients with congestive heart failure (CHF) [205]. Based on findings from 
observational evidence, metformin was found to be associated with a lower risk of all-cause 
mortality when compared to non-metformin treatment in patients with treated T2D and CKD 
or CHF. 
Furthermore, there were no new cases of MALA for patients with CHF and there was no data 
to suggest higher incidences of lactic acidosis with metformin use in older adults. Based on 
limited available evidence, the comparative risk of MALA in patients with CKD and CHF does 
not appear to be higher than the risks with the use of other hypoglycemic medications, hence 
the benefits of metformin use in CKD and CHF outweigh the risks [205]. 
 
 1.10.2 Metformin and vitamin B12 
 
Long-term use of metformin is associated with vitamin B12 malabsorption that may be due to 
its effects on calcium-dependent membrane action and the cobalamine-IF uptake by ileal cell 
receptors leading to reduced vitamin B12 absorption [206]. Metformin interferes with vitamin 
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B12 intrinsic factor complex hence vitamin B12 absorption. However, there is evidence that 
dietary calcium supplementation reverses metformin-induced vitamin B12 malabsorption [207]. 
Although clinical significance of this is not yet clear, it is believed that bacterial overgrowth 
could also cause reduction of vitamin B12 absorption through increased binding of bacterial 
cells to vitamin B12-IF complexes [208] . 
T2D is a progressive and complex disorder that is difficult to treat effectively in the long term. 
The majority of patients are overweight or obese at diagnosis and will be unable to achieve or 
sustain normal blood glucose without oral antidiabetic agents [209]. Recently new drugs have 
markedly expanded and improved therapeutic options, however, blood glucose control is not 
optimized despite the presence of this new medication. Adverse-events especially 
hypoglycemia and weight gain, are still frequent and decrease treatment adherence.  
 
1.10.3 Antihyperglycemic effects of metformin  
 
Metformin exerts its antihyperglycemic effects primarily by inhibiting hepatic gluconeogenesis 
and by enhancing effects of insulin in certain target organs like muscles and adipose tissues 
[210, 211]. It has been shown to reduce glycosylated hemoglobin by 1.1–3.0% in T2D patients 
[212]. Metformin acts in the liver to suppress gluconeogenesis mainly by potentiating the 
effects of insulin, reducing hepatic metabolism of lactate and opposing the effects of glucagon 
[213].  
Additionally, metformin can reduce the overall rate of glycogenolysis through AMPK 
activation, which leads to suppression of gluconeogenic enzymes. Metformin improves insulin 
sensitivity by increasing insulin-mediated insulin receptor tyrosine kinase activity which 
activates post-receptor insulin signaling pathways. This has been attributed in part to increased 
translocation of insulin-sensitive glucose transporters to the plasma membrane [214, 215].  
However, loss of glycemic control with traditional combinations with insulin, sulfonylureas or 
thiazolidinediones has recently led to combination of metformin with newer agents such as 
SGLT-2 antagonists (e.g. gliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, 
luseogliflozin, tofogliflozin),  GLP-1 analogs or Dipeptidyl peptidase 4 (DPP-4) inhibitors 
(such as exenatide, liraglutide, linagliptin, saxagliptin, sitagliptin, teneligliptin) with 
concomitant amplification of adverse effects not commonly experienced with metformin 
monotherapy [216, 217]. 
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1.11 Non-glycemic effects of metformin 
1.11.1 Inflammation and hematological effects of metformin  
 
Metformin has recently been shown to prevent atherosclerosis by improving endothelial-
dependent vasodilation, inhibiting vascular inflammation by AMPK activation in diabetic rats 
[218]. AMPK has recently been shown to ameliorate anemia when activated by metformin 
[219, 220]. Activation of AMPK leads to phosphorylation of eNOS, thus stimulating the release 
of NO that is important for vascular function [221]. In agreement with this, metformin 
improved endothelial function in vivo, by reducing endoplasmic reticulum stress, superoxide 
production and increasing NO bioavailability in mice on a high-fat diet [222], an effect that 
involved AMPK or Peroxisome Proliferator-activated Receptor δ (PPAR δ) pathways [223]. 
Furthermore, metformin has been shown to suppress inflammatory response in an otitis media 
model by relieving oxidative stress prevent thrombosis and inhibiting platelet activation by 
reducing mitochondrial free radical overload [224, 225]. 
 
 1.11.2 Antidyslipidemic effects  
 
Dyslipidemia is major contributor to increased cardiovascular risk associated with T2D and it   
encompasses abnormalities in all lipoproteins [226]. Patients usually present with elevated total 
cholesterol, low Density lipoprotein cholesterol (LDL-c), triglycerides (TG) and reduced high 
density lipoprotein cholesterol (HDL-c) which significantly increase the risk of cardiovascular 
disease in these patients [227, 228]. Metformin has pleiotropic effects and can be useful in 
diabetic dyslipidemia, diabetic cardiomyopathy and vascular dysfunctions [229].  
It has been shown to decrease total cholesterol, LDL-c, plasma free fatty acids and TG and may 
even increase HDL-c [230, 231]. Favorable effects on HDL-c and LDL-c in people who do not 
have diabetes have also been reported with metformin therapy. In a large retrospective study 
analysis, metformin has been shown to lower TG and increase HDL-c in diabetic patients [232] 
and has been reported to enhance therapeutic outcomes on atherogenesis with statins in patients 
with T2D [232]. These effects of metformin appear to be exerted by activation of AMPK which 
switches energy balance from anabolic to catabolic state leading to inhibition of glucose, 
protein and lipid synthesis but increased fatty acid oxidation and glucose uptake [233]. 
 
 1.11.3 Metformin effects on hypertension and cardiovascular morbidity 
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Cardiovascular morbidity and hypertension are common end-points of diabetes complications 
[234]. Diabetes is associated with increased progression of asymptomatic left ventricular 
dysfunction and symptomatic HF, increased hospitalizations for HF, and an overall increased 
mortality risk in patients with chronic HF [235, 236]. Metformin has been shown by the 
UKPDS study to reduce cardiovascular disease risks in T2D patients [186, 236]. A prospective 
observational study as well as a retrospective cohort study have provided evidence that 
metformin use was associated with decreased incidence of atherosclerosis and myocardial 
infarction or stroke [237, 238]. 
 Clinical and experimental evidence so far presented suggest that non-glycemic 
cardioprotective effects of metformin are mediated by activation of AMPK and eNOS and 
several kinases of the reperfusion injury salvage kinase (RISK) signaling pathway that prevent 
mitochondrial permeability transition pore (MPTP) opening and reperfusion [239, 240]. 
Despite initially conflicting reports on the effects of metformin on blood pressure, it has now 
become apparent that metformin actually normalizes blood pressure in hypertensive 
individuals but does not affect blood pressure in normotensive individuals [188].  
These effects of metformin on blood pressure are thought to be related to the lowering of 
plasma norepinephrine levels leading to a decrease in cardiac sympathetic tone and reduced 
workload and myocardial fat oxidation [241, 242]. These effects are consistent with decreased 
myocardial oxygen consumption (mVO2) and decreased myocardial sympathetic activity [188].  
 
1.11.4 Polycystic ovarian syndrome (PCOS) 
 
Polycystic ovarian syndrome (PCOS) described, as a syndrome of ovarian dysfunction is the 
most common endocrine disorder affecting 4–12% of women of reproductive age [243, 244]. 
PCOS is characterized by chronic oligo- or an-ovulation presenting with menstrual 
irregularities, hirsutism, infertility and elevated serum testosterone and androstenedione [245, 
246]. Obesity, insulin resistance and hyperinsulinemia are the hallmarks of PCOS [247]. 
Insulin resistance appears to be the link between PCOS and T2D, with other recognized 
cardiovascular risk factors such as dyslipidemia and hypertension, as well as with anatomical 
and functional cardiovascular derangement [244]. Metformin has been shown to reduce 
systolic blood pressure, hyperinsulinemia and follicle stimulating hormone (FSH) in women 
with PCOS [248]. Furthermore, metformin may increase ovulation, improve the menstrual 
cycle, reduce serum androgen levels and may improve hirsutism [244].  
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1.11.5 Antineoplastic effects of metformin 
 
Patients with T2D have an increased risk of malignancy compared to non-diabetic patients 
particularly liver, pancreas, endometrium, colon, rectum, breast, and bladder cancer [249, 250]. 
Persistent insulin resistance and hyperinsulinemia in T2D activate Insulin Growth Factor-1 
(IGF-1) which is a potent mitogen [251, 252]. Most cancer cells can also overproduce insulin 
receptors most commonly as the α-isoforms, which can stimulate insulin-mediated mitogenesis 
even when IGF-1 receptors are deficient.  
Activation of the insulin receptor is essential for promoting cell survival and division in cancer 
cells and these growth-promoting effects of the IGF insulin axis may extend to normal smooth 
muscle cells, thus establishing a common pathway for accelerated atherosclerosis and 
accelerated cancer development in diabetes [253, 254]. Metformin usage has been 
demonstrated to be inversely related to the incidences of many types of cancers such as breast, 
ovarian, endometrial and colorectal cancers in T2D patients and clinical trials with metformin 
have now been extended to non-diabetic populations [255, 256].  
Antineoplastic effects of metformin have been shown to be mediated by the activation of the 
LBK1-AMPK signaling pathway which inhibits Mammalian Target of Rapamycin (mTOR),a 
critical mediator of Phosphatidylinositol- 3-kinase/protein kinase B/akt (PI3K/PKB/Akt) 
which is the most frequently dysregulated signaling pathway in oncogenesis [257, 258].  
Other mechanisms of metformin anti-cancer effects include its ability to reduce circulating 
plasma insulin and IGF-1 concentrations hence limiting the risk of hepatocellular carcinoma 
[259] and stimulating tumour specific CD8 ⁠+ cells which initiate expansion and differentiation 
of effector cytotoxic T lymphocytes leading to apoptosis [260, 261]. Some in vitro and in vivo 
studies strongly suggest that metformin may be a valuable adjuvant in cancer treatment because 
of lower risk of cancer in patients who use the drug [262]. 
 
1.12 Mechanism of action of metformin 
 Metformin uptake into hepatocytes is facilitated by the organic cation transporter protein 
(OCT1), where it accumulates in the liver. It directly inhibits RCC1 leading to a decrease of 
both cytosolic and mitochondrial adenosine triphosphate /adenosine diphosphate (ATP/ADP) 
ratio, serving as an allosteric activator of 5’-AMP-Activated Protein Kinase  (AMPK) (Fig. 2) 
[263]. Decreased electron transport chain activity suppresses tricarboxylic acid cycle flux and 
decreases mitochondrial ATP synthesis causing cellular energy stress and elevation of the 
AMP: ATP ratio.  
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AMPK is a primary metabolic sensor that is phosphorylated by the upstream kinases LKB1 
and Ca2+/Calmodulin-dependent Protein Kinase Kinase beta (CaMKKβ) [264]. LKB1 is an 
important upstream kinase of AMPK cascade in mammalian cells that phosphorylates 
Threonine (Thr) 172 on the activation loop of AMPK catalytic subunit and subsequently 
activates AMPK in-vitro [265]. In addition, inhibition of LKB1 activity in cells simultaneously 
abolishes the activation of AMPK by different stimuli.  
Metformin most likely does not directly activate either LKB1 or AMPK, as it does not 
influence the phosphorylation of AMPK by LKB1 in a cell-free assay [266]. Rather, there is 
evidence that AMPK activation by metformin is secondary to its effect on mitochondria, the 
primary target of the drug [267]. At cellular level, metformin activates AMPK by 
phosphorylation, which suppresses glucagon-stimulated glucose production, and causes 
increased glucose uptake by hepatocytes and skeletal muscles [268]. 
AMPK activation in the skeletal muscles also increases glucose consumption and is another 
potential site of metformin action. Both of these consequences of metformin lower blood 
glucose and contribute to therapeutic benefits in T2D [265, 269]. 
 
 
Figure 7. Known and proposed mechanisms of action of metformin in hepatocytes. AMP 
(Adenosine Monophosphate Protein); AMPK (Adenosine Monophosphate-Activated Protein 
Kinase); ATP (Adenosine Triphosphate); OCT1 (Organic Cation Transporter 1); PKA (Protein 
Kinase A); ACC; (Acetyl-CoA Carboxylase); SIRT1; SREBP1, (Sterol Regulatory Element-
Binding Protein-1); LKB1 (Liver Kinase B1) [268]. 
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Metformin’s primary benefit in T2D has been in its ability to slow down the accelerated basal 
rates of hepatic gluconeogenesis without an apparent effect on lactate turnover for 
gluconeogenesis or increases in insulin secretion. Metformin suppresses hepatic glucose output 
through the down-regulation of the transcription of the rate-limiting gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) [270, 
271]. 
Metformin activates LKB1 thereby resulting in the phosphorylation of  AMPK and cytosolic 
isolation of the cAMP Response Element Binding protein (CREB) transcription factor 
transducer of regulated CREB coactivator 2 (TORC2) [272]. It is then trapped in the cytosol 
of the hepatocyte CREB within the nucleus that is efficient at transcribing a transcriptional 
cofactor named PGC1α [273]. Resultant low amounts of PGC1 α causes less transcriptional 
activation of G6Pase and PEPCK thereby leading to a slowing down of the accelerated basal 
rates of hepatic gluconeogenesis (Fig. 7) [267].  
Therefore, the success of metformin in T2D and cardiovascular diseases is dependent on 
AMPK activation despite its limited drawbacks. However, some patients still fail to obtain 
optimum glycemic control with metformin. The most common side-effects of metformin are 
GI disturbances, metformin associated lactic acidosis and vitamin B12 malabsorptions. Would 
phytochemicals with similar pharmacological effects but devoid of side-effects therefore be 
more beneficial? What are the potential implications of concurrent consumption of naringenin 
with metformin? 
1.13 Plant-derived alternatives 
Flavonoids constitute the most abundant bioactive constituents of the grapefruit and four types 
of flavonoids (flavanones, flavones, flavonols and anthocyanins) have been identified in the 
citrus fruits [274, 275]. The chemical skeleton structure of flavonoids is based on a 15-carbon 
skeleton consisting of two benzene rings (A and B) linked via a heterocyclic pyrane ring (C) 
(Fig.8 ) [276]. Chalconoids commonly known as chalcones are a group of compounds that are 
classed as minor flavonoids as they also contain the C6-C3-C6 backbone [277]. The flavonoids 
are well-known by many biological activities which includes  protective effects such as anti-
oxidant, vasorelaxant and anti-thrombotic properties [278]. It has been suggested that 
flavonoids decrease the risk of coronary heart disease by three major actions which are 
improving coronary vasodilatation, decreasing the ability of platelets in the blood to clot, and 
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preventing LDLs from oxidizing [275, 279]. Naringin is the major flavanone found in 
grapefruit which possesses the distinct bitter taste with other flavanone hesperidin [280]. 
 
 
Figure 8. Skeleton structure of flavonoids. 
 
Naringin has two rhamnose units attached to its aglycone portion. On the other hand, 
naringenin (4′, 5, 7-trihydroxyflavanone 7-rhamnoglucoside) like all flavonoids has a chemical 
structure based on a 15-carbon skeleton consisting of two benzene rings (A and B) linked via 
a heterocyclic pyrane ring (C) (Fig. 8) [276]. Upon ingestion, naringin is hydrolyzed by 
intestinal bacterial naringinase complex to its aglycone naringenin, which appears to be 
biologically more potent [280, 281]. Naringin is rapidly converted to naringenin whether 
administered orally or IV by either intestinal bacterial or hepatic metabolism, respectively 
[281]. We have recently reviewed the pharmacological evidence that show similarities between 
metformin and naringenin and proposed that naringenin can be used as adjunct or therapeutic 
substitute to metformin given their similarities in pharmacological actions (Fig. 9) [282]. 
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Figure 10. Chemical structures of A: metformin and B: naringenin. ChemDraw, PerkinElmer®  
 
  
 
 
Figure 9. Enzymatic hydrolysis of naringin. Naringinase is an enzymatic complex with α- 
rhamnosidase activity which hydrolyses naringin to prunin and rhamnose, and β glucosidase 
activity which in turn hydrolyses prunin to naringenin and glucose, respectively [278, 283]. 
1.13.1 Antihyperglycemic effects of flavonoids  
 
Citrus derived flavonoid, naringin or its aglycone naringenin have been shown to have 
antidiabetic, antidyslipidemic and cardioprotective effects and may reduce the risk of age-
related chronic diseases [278, 280, 284, 285]. The antidiabetic properties of flavonoids are 
mainly through their effects on a number of molecular targets and regulation of several 
pathways such as reducing apoptosis, improving proliferation of pancreatic β-cells and 
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promoting insulin secretion [284]. Moreover, flavonoids regulate glucose metabolism in 
hepatocytes with subsequent improvement of hyperglycemia and decrease in insulin resistance 
[286]. Uptake of glucose by the cells is an important phenomenon in normalizing blood glucose 
levels and there are pharmacological evidences regarding beneficial effects of flavonoids on 
peripheral glucose uptake in both insulin sensitive and non-insulin sensitive tissues [49].  
Antihyperglycemic effects of naringenin have been described in experimental animal models 
[287, 288]. This is in tandem with observations that grapefruit or its main flavonoid naringin, 
a naringenin glycone, has antihyperglycemic effects mediated by downregulation of hepatic 
PEPCK and G6Pase, respectively [289].  
Furthermore, naringin has been reported to increase insulin sensitivity by enhancing tyrosine 
phosphorylation [290] suggesting its ability to relieve insulin resistance and also enhance 
glucose uptake in skeletal muscles perhaps by antagonising glucagon signaling pathways 
similarly to metformin, amongst others  [278, 291, 292].  
These observations, therefore, strongly suggest that naringenin alone or synegistically with 
other flavanoids have potential antidiabetic activity which could be mediated by AMPK, which 
is known to increase glucose uptake, fatty acid uptake and utilisation, and glycolysis in the 
heart and other peripheral tissues. Furthermore, six homoisoflavonoids and one 
dihydrochalcone have been reported to have antidiabetic effects by activating AMPK [293].  
1.13.2 Antidyslipidemic effects of naringenin  
 
It was previously reported that naringin, improved diabetic dyslipidemia in experimental 
animal models by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA 
reductase) and Acyl-CoA: cholesterol acyltransferase (ACAT) which catalyze rate-limiting 
steps in cholesterol biosynthesis [294], similarly to previously published studies [295, 296]. 
Naringenin has been shown to prevent atherosclerosis in Ldlr−/− mice by preventing production 
and increasing oxidation of FFA, preventing hepatic steatosis, and overproduction of very low 
density lipoproteins (VLDL) [297].  
Furthermore, naringenin ingestion was associated with lipid-lowering effects, reduced plasma 
markers of endothelial dysfunction and improved insulin sensitivity [298, 299]. Naringenin has 
further been shown to prevent dyslipidemia by preventing apoprotein B overproduction 
through activation of PPARα gene transcription and upregulation of its fatty acid oxidation 
downstream effectors [300, 301].  
It has also been demonstrated that naringenin inhibits secretion of apoB-containing lipoproteins 
primarily by limiting the accumulation of TG in the endoplasmic reticulum (ER) lumen [295], 
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secondary to microsomal triglyceride transfer protein (MTTP) inhibition and activity leading 
to increase in the expression and activity of the LDLR [301, 302]. Naringenin protects against 
intercellular adhesion molecule-1(ICAM-1), suppress macrophage inflammation, inhibit 
leukotriene B4, monocyte adhesion and foam cell formation, induce of Heme Oxygenase1 
(HO-1) and G0/G1 cell cycle arrest in vascular smooth muscle cells (VSMC) [303]. These 
events eventually downregulate atherosclerosis-related genes which are believed to play crucial 
roles in atherosclerosis [303]. Like metformin, antidyslipidemic and antiatherogenic effects of 
naringenin therefore appear to be effected by AMPK-mediated pathways [301]. 
1.13.3 Antioxidant effects of naringenin  
 
Antioxidant activities of naringenin and other flavanones have intensively been investigated. 
Naringenin has previously been shown to boost antioxidant capacity in vivo by increasing 
hepatic concentrations of catalase, superoxide dismutase and glutathione reductase [304] to 
confer renoprotective effects by relieving oxidative stress in streptozotocin-induced diabetes 
[305] and to ameliorate daunorubicin-induced nephrotoxicity by mitigating AT1R, ERK1/2-
NFκB p65 mediated inflammation [306]. Antioxidant effects of naringenin appear to be largely 
mediated by free radical scavenging effects due to the phenolic hydroxyl groups attached to 
the flavonoid structure [306, 307]. It appears from experimental evidence adduced so far that 
antioxidant effects of metformin and naringenin could be the convergence point of their 
overlapping pharmacological effects. 
 
1.13.4 Naringenin effects on hypertension and cardiovascular morbidity 
 
It has been have reported that naringin, a naringenin glycone, relieves hyperglycemia-induced 
cardiac fibrosis and cardiac hypertrophy in diabetic rats [308] and has general cardioprotective 
effects under experimental conditions [309, 310]. Recently, protective effects of naringenin on 
cardiorenal syndrome have been reported where it mitigated cardiac remodeling, cardiac 
dysfunction and left ventricular diastolic pressure in experimental animals [311]. Naringenin 
supplementation was found to improve hypertension in high-carbohydrate fed rats and stroke-
prone hypertensive rats. Calcium-dependent K channels are important regulators of vascular 
relaxation and naringenin has been shown to activate large conductance of Ca2+activated K+ 
currents in a concentration-dependent manner in rat tail artery myocytes [280]. 
These actions of naringenin are suggested to be consequence of its antioxidant effects that 
activate AMPK, PPARα–, MAP kinase-mediated signaling pathways [308, 312].  
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1.13.5 Antineoplastic effects of flavonoids  
 
On the other hand, antineoplastic potential of naringenin is currently gaining recognition. 
Naringenin has recently been shown to have pro-apoptotic and chemo-sensitizing effects that 
halt the cell cycle, upregulate pro-apoptotic genes and inhibit procell survival signaling 
pathways in vitro [313]. It has been shown that naringenin inhibits proliferation of colon cancer 
and melanoma cells and reduces migration of neoplastic hepatoma and pancreatic cancer cells 
[314] amongst others.  
Other studies have suggested that naringenin may have tamoxifen-like effects on breast cancer 
cell lines and induces apoptosis by activating STAT3 and NF-κB [315]. However, detailed 
molecular mechanisms of its anti-proliferative effects and apoptosis induction are yet to be 
determined although experimental evidence currently suggest that anti-neoplastic effects of 
naringenin similarly to metformin are mediated by PI3K/AKT and MAP kinase signaling 
pathways [316]. Even though experimental evidence is largely based in in vitro, naringenin 
appears to have the potential to be a useful adjunct to chemotherapeutic agents in the treatment 
of human cancers [313]. 
 
1.13.6 Inflammation and hematological effects of naringenin 
 
Naringenin has been shown to inhibit leukocyte recruitment, reduce oxidative stress and boost 
antioxidant capacity by activating macrophage Nuclear Factor erythroid 2-Related factor 
2 (Nrf2) which induces HO-1 expression and also suppress activation of Nuclear Factor-κB 
(NF-κB) in macrophages which causes production of pro-hyperalgesic cytokines such as 
Interleukin- 33 (IL-33), TNF-α, Interleukin-1 β (IL-1β) and Interleukin-6 (IL-6) [317, 318]. 
Naringenin has further been reported to prevent cholesterol-induced systemic inflammation 
and atherosclerosis, suppress production of pro-inflammatory cytokines in murine 
endotoxaemia model by inhibiting the NF-κB and MAP kinase signaling pathways and also 
reducing platelet activation [239, 319, 320]. Both metformin and naringenin therefore appear 
to exert anti-inflammatory effects through similar molecular signaling pathways by relieving 
oxidative stress in both in vivo and in vitro studies [320]. 
 
1.14 AMPK activation, an attractive target in T2D 
 
AMPK is a major cellular regulator of lipid and glucose metabolism. Recent evidence shows 
that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profiles, 
37 
 
blood pressure and insulin-resistance making it a novel therapeutic target in the treatment of 
T2D [321]. It is worth mentioning that the gold standard first-line treatment of T2D, metformin 
acts by activating AMPK through inhibition of RCC 1 leading to a decrease in both cytosolic 
and mitochondrial ATP/ADP ratio [266, 322]. Animal model studies with metabolic syndrome 
phenotypes have exhibited decreased AMPK activity in the muscles and evidence exists that 
AMPK activity is diminished in the skeletal muscle or adipose of humans with T2D or obesity 
[321, 323, 324]. Therefore, AMPK seems to be an attractive and promising target for the 
pharmacological treatment of T2D. 
AMPK is a serine/threonine enzyme that mediates cellular homeostasis and controls key 
players of metabolic pathways [272]. AMPK exists as a complex of three subunits, the catalytic 
α1&2 subunit with an N-terminal kinase domain (KD) and the regulatory subunits β and γ; the 
α catalytic subunit has a Ser/Thr domain that has to be phosphorylated to ensure enzyme 
activity (an α1 catalytic subunit that is active in the absence of γ & β subunits has been 
constructed; identifying an auto-inhibitory sequence between amino acid 313-392) [325]. 
 The β subunit has glycogen-binding domains (GBD) which are suggested to facilitate the 
binding of AMPK to its substrate glycogen synthase and also serve as glycogen concentration 
sensors in the cell to mediate the synthesis of glycogen in response to glycogen and energy 
levels of the cell. The γ subunit regulates the activity of the enzyme by sensing cellular 
concentrations of AMP, ADP and ATP in the cell [272].  The γ subunit of AMPK also contains 
four copies of the Cystathionine β-synthase (CBS) sequence. Alexander Bateman first 
recognized CBS sequence by looking at internal sequence duplications within proteins of 
methanococcusganaschii genome [326]. 
 AMPK activation is due to phosphorylation of Thr172 in the activation loop of α subunit and 
it is achieved by upstream kinases that include LKB1 and CaMKKβ [327]. Catalysis of AMPK 
is attributable to LKB1:STRAD:MO25 complex in response to increase in the AMP/ATP ratio 
which comes as a result of elevated Ca 2+ levels by CaMKKβ (Fig. 11). Binding of AMP and 
ADP at the γ subunit results in activation of AMPK thereby promoting phosphorylation of 
Thr172 by upstream kinases and inhibiting dephosphorylation by protein phosphatases thus 
allowing AMP and ADP as allosteric activators of AMPK [272].    
Thr172 is dephosphorylated by Protein Phosphatase 2C (PP2C) switching active AMPK to the 
inactive form [328].  
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Figure 11. Regulation of AMPK activation [328]. 
 
 Role of AMPK in regulation of lipid and glucose metabolism in the skeletal muscles. AMPK 
activity may be increased by an altered AMP or by hormonal action resulting in increased 
glucose transport as well as increased fatty acid oxidation as shown (Fig. 12) [328]. 
 
 
 
 
Figure 12. AMPK regulation of metabolism in the skeletal muscle; ACC, acetyl-CoA 
carboxylase; AMPK; (AMP-activated protein kinase); AS160, (Akt substrate of 160 kDa); 
CPT1-α, (Carnitine Palmitoyl Transferase-1); Glut4, (Glucose transporter 4); MCD, Malonyl-
CoA Decarboxylase); PGC1α, PPARγ co-activator 1α; LCACoA, (Long Chain Acyl CoAs) 
[328]. In T2D, insulin fails to suppress gluconeogenesis and hepatic glucose production. 
AMPK suppresses gluconeogenesis by inhibiting the transcription of key regulatory 
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gluconeogenic enzymes PEPCK, G6Pase, and further inhibiting the synthesis of glycogen by 
deactivating glycogen synthase in hepatocytes. It will then downregulates the expression of 
gluconeogenic enzymes by inhibiting the transcription factors ChREBP and HNF-4 α [272].   
 
1.15 Rationale and motivation 
Naringenin has been shown to cause AMPK activation in L6 myotubes resulting in the 
enhancement of insulin sensitivity and a decrease in blood glucose levels in diabetic animal 
models [329]. The pharmacological and molecular similarities between metformin and 
naringenin have shown that naringenin can be used as an adjunct or substitute to metformin 
given the similarities, however the efficacy of naringenin could be limited due to presence of 
3-OH groups attached to benzene rings [330].  
Recent evidence shows that pharmacological activation of AMPK improves blood glucose 
homeostasis, lipid profiles, blood pressure and insulin-resistance making it a novel 
therapeutic targets in the treatment of T2D [322]. It has been shown that naringenin exerts its 
antidiabetic effects by inhibition of gluconeogenesis through upregulation of AMPK hence 
metformin-like effects. Naringin has further been shown to have non-glycemic affects like 
metformin that mitigate inflammation and cell proliferation. 
 Because of these similar pharmacological effects between naringenin and metformin, our 
laboratory has synthesized analogs of chalco-naringenin compounds which could be more 
permeable to the plasma membrane and hence putatively increase pharmacological effects. 
These compounds have nitro-groups attached to the benzene ring that are highly electron 
withdrawing and hence have shown good binding affinity to their target enzymes in silico. The 
structures of compounds were characterized, based on their spectroscopic data obtained from 
proton and carbon NMR and FT-IR. We propose that the lipophilic nature of these compounds 
could enhance permeation of cell membrane and therefore improve the binding affinity to 
AMPK.  
If the compounds bind to AMPK, we hypothezise that they can activate it hence metformin-
like effects [282].  
The evidence of potential AMPK activation by these compounds was obtained through 
computational chemistry techniques by docking to enzyme. The synthesized compounds were 
shown to fit very well in the hydrophobic binding pockets of AMPK and presented the good 
binding affinity to their enzymes through computer simulation. Therefore, we hypothesize 
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those synthetic analogs of chalco-naringenin would possesses antidiabetic activity, and could 
be potential agents for the treatment for T2D.  
1.16 Aim:  
To investigate the effects of synthetic chalco-naringenin analogs on the expression of 
AMPK in-vitro. 
     1.17 Objectives: 
i. To determine effects of chalco- naringenin analogs on cell viability and apoptosis. 
ii. To determine the effects of chalco-naringenin analogs on quantitative expression 
of AMPK protein in-vitro. 
iii. To determine the effects of chalco-naringenin analogs on glycogen synthesis in 
C2C12 and Chang cell lines. 
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Chapter   Two 
Experimental 
2.1 Materials and Chemicals 
The skeletal muscle cell lines (C2C12) and Chang were purchased from European Collection 
of Cell Cultures (ECACC). Unless otherwise stated, all chemicals and reagents used were 
purchased from Sigma-Aldrich™ (SA). The chalco-naringenin analogs were synthesized in 
Department of Pharmacology and Pharmaceutical chemistry UKZN. Enzyme Linked-Immuno-
Sorbent Assay (ELISA) kit was purchased from Biocom Diagnostics Africa. 
2.2. Synthesis of the minor flavonoids (chalcones) 
Chalcones/chalconoids are primarily synthesized using Claisen-Schmidt reaction; in this 
reaction, acetophenone is reacted with benzaldehyde in the presence of a strong base such as 
sodium hydroxide (NaOH), potassium hydroxide (KOH) or sodium hydride (NaH) as a catalyst 
in a polar solvent (scheme 1) [331]. 
 
Figure 13: Claisen-Schmidt reaction, chalcone synthesis. 
 
A series of 11 compounds of 4-[(cyclopropylcarbonyl) amino] chalco-naringenin analogues 
were synthesized using Claisen-Schmidt and characterized by  1H-NMR and 13 C-NMR using a 
BrukerAvance III 400MHz spectrometer, the solvent that was used to dissolve compounds for 
NMR submission was deuterated chloroform (CDCl3) and Infrared spectroscopy using a Perkin 
Elmer spectrum 100 FT-IR spectrophotometer . Characterization of compounds was also done 
using melting point determination by electrothermal 9300 digital melting point apparatus.  The 
progress of reactions and their completion was monitored using analytical Thin Layer 
Chromatography (TLC) performed on plates pre-coated with silica gel (Merck 60F254, 0.25mm). 
Computer docking simulation studies against AMPK were done.  
2.3 In silico evaluation: Docking 
The 3-D complex structures of AMPK were obtained from the protein data bank using PDB 
code 4CFH. The enzyme was then isolated from the ligand using Molegro Molecular Viewer 
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(MMV) software suite (www.nlcbio.com).The free enzymes were then used in all subsequent 
computational calculations. The 2D structures of compound 5a-5k were drawn using the 
chemical structure drawing package - Chemdraw Ultra. Docking was done on Auto-dock Vina 
version 4, ligand interaction was done on Maestro software and visualization of poses and 
conformations was done on chimera software. 
To this end, all these ligands were docked into the active site of AMPK.  The docked compounds 
were then ranked according to the binding affinities against the target protein. 
To validate the docking approach used in this study, the same docking procedure was applied 
to the experimentally determined compounds with known inhibitory properties of the respective 
enzymes. They were removed and re-docked into their respective enzymes and their binding 
affinities have been reported. 
 
 
2.4 Cell culture 
The C2C12 and Chang cells were cultured within 40 passages in 75 cm3 flasks in DMEM with 
4500 mg/L glucose and EMEM media containing supplemented with 10% fetal bovine serum 
(FBS), 10% penicillin-streptomycin, 10.0 mM HEPES and 1.0 mM sodium pyruvate. The 
cultures were maintained at 37°C in humidified air with 5% CO2. 
2.5 Trypsinization and cell counting 
Trypsinization was done to detach cells from the culturing vessel once they reached 80% 
confluency, and to sub-culture and seed the cells for the various biochemical assays.  This 
process involved rinsing the cells three times with warm 0.1M PBS (3 ml; 37°C) and incubating 
the cells with trypsin-EDTA (1 ml) for 2 min. The cells were then observed for roundness using 
an inverted light microscope (Olympus IXSI; 20 x).  Once they were found to be round, trypsin 
was discarded and Cell Culture Medium (CCM) (5 ml) added to the flasks which were agitated 
to remove cells from the culturing vessel and the cell suspension was counted using 
hemocytometer. Trypan blue (0.4%) was applied in a dye exclusion procedure for cell 
counting. The principle of dye exclusion is based on damaged/dead cell membranes that allow 
entry of the dye into the cells and the cells stain blue whereas sustainable cells remain 
unstained. 
43 
 
2.6 Chalcones and positive controls preparation 
Metformin and naringenin were dissolved in 100 % Dimethyl sulfoxide (DMSO) suitable for 
cell culture to a stock concentration of 4.0 mg/ 2 mls (15 mM) and 4.1 mg/ml (15 mM), 
respectively. Chalco-naringenin analogs (2-chlorophenyl and 2,3-dimethoxy phenyl) were 
dissolved in DMSO to a final concentration of 10 mg/ 2 mls and 10.8 mg/ 2 mls to 15 mM, 
respectively.  
2.7 Cell Exposure 
Cells were exposed to metformin (2, 5, 10, 12.5 mM), naringenin (50, 100, 200, 300, 500 μM), 
2-chlophenyl (5b) (10, 20, 50, 100, 200 and 500 μM) and 2,3-dimethoxyphenyl (5k) (10, 20, 
50, 100, 200 and 500 μM for 12 hours, 24 hours and 48 hours for viability and IC50 
determination using colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltretrazolium 
bromide (MTT) assay.  The doses of compounds used were similar to naringenin doses used in 
the previous studies. We decided to use similar doses to naringenin because these newly 
synrhisezed compounds are derived from naringenin although some chemical properties may 
differ somehow. To determine the effects of chalcones on AMPK, the cells were plated in 6-
wells plates (5.0× 105 cells/well) in the presence of 11 mM glucose only and allowed to grow 
to 80% confluence, followed by treatment with metformin (2, 10, mM), naringenin (50, 200, 
300,500 μM), 2-chlophenyl (5b) (10, 20, 50, 100, 200 and 500 μM) and 2,3-dimethoxyphenyl 
(5K) (10, 20, 50, 100, 200 and 500 μM) for 24 hours. Co-treatment of cells with positive 
controls (naringenin and metformin) plus test compounds was also done. Cells were harvested 
and stored at -80 °C for glycogen determination and a glucose uptake assay. Vehicle controls 
constituted Cell Culture Medium (CCM) with or without chalcones were applicable. After the 
treatments, cells were harvested, protein determination was done and further biochemical 
analyses (Fig. 4). 
 
2.8 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) Assay 
Cell viability was assessed by MTT assay that is based on the conversion of MTT to MTT-
formazan by mitochondrial enzymes. Cells (1.5 x 104) were aliquoted into a 96-well plates and 
incubated in wells containing 100 μl cell culture medium with 11.0 mM glucose, 20 μl of MTT 
(stock solution 8.0 mg/1.6 mls MTT in PBS) at 37°C for 4 hours. The cells were previously 
treated with metformin (2-12.5 mM), naringenin (50-500 μM) and chalcones (10-500 μM) at 
three different time intervals (12, 24, and 48) hours. MTT salt solutions were discarded and 
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100 μl of DMSO added to each well then incubated for 1.0 hour at 37° C to solubilize formazan 
crystals. All experiments were performed independently in triplicates. The absorbance was read 
at 570 nm with EZ 400 microplate reader (Biochrom Ltd, Cambridge, UK). The percentage of 
cell viability was obtained using the optical density readings of chalcones treated cells 
compared to those of untreated cells (control), where percentage viability = [A]test / [A] control 
*100, where [A]test is the absorbance of the test sample and [A]control is the absorbance of control 
sample. 
 
 
 
 
 
2.9 Flow diagram of experimental protocol 
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Figure 14. Flow diagram of experimental protocol. 
 
 
2.10 Glycogen Determination 
Glycogen measurement was performed in the liver (Chang) and muscle (C212) cell lines 
harvested after 24 hours incubation. According to Seifter et al. (1950), harvested cells (1x106 
per mL) were put into a test tube and heated with 2 ml of 30% KOH at 100°C for 30 minutes 
[332]. The reaction was stopped by adding Na2SO4 (10%, 0.194 mL) into the test tube and then 
allowed to cool. The cooled mixture (200 µl) was aspirated and mixed with (95%, 200 µl) 
ethanol for glycogen precipitation. The precipitated glycogen pellet was washed and allowed 
to solubilize in distilled water (1.0 mL). Thereafter, anthrone (0.5g dissolved in 250 mL of 
sulphuric acid, 4 mL) was added and boiled for 10 minutes and allowed to cool down. After 
cooling, the absorbance was read using the spectrostar Nano spectrophotometer at 620 nm. 
Glycogen concentrations were calculated from the glycogen standard curve (Glycogen 
concentration (μg/ml) = CSF - (y-intercept)/ Slope * Sample dilution 
CSF= sample fluorescence (CSF) for each sample 
2.11 Determination of AMPK by Phospho-AMPK α (Thr172) Sandwich ELISA kit 
Treated cells were collected by adding fresh media with low speed centrifugation (1200 rpm). 
Cells were washed three times with 5-10 ml ice-cold 1X PBS. Cells were then harvested from 
5 mls of growth media and then lysed in 2.0 ml of 1X Cell Lysis Buffer plus 1 mM 
Phenylmethylsulfonyl Fluoride (PMSF). Lysates were sonicated on ice for 2 minutes. Cell 
lysates were micro centrifuged for 10 min at 14,000 rpm at 4°C and supernatant was transferred 
to a new tube. Cell lysates were stored at −80°C in single-use aliquots. Cell lysates were then 
diluted with sample diluent. An aliquot of 100 μl of each diluted cell lysate was aspirated in 
the appropriate well in the 96-well plate. The plate was sealed with tape and firmly pressed on 
top of micro wells. The plate was incubated for 2 hours at 37°C. The tape was then gently 
removed and each well was washed 4 times with 1X Wash Buffer, 200 μl each time. 
Reconstituted detection antibody (100 μl) was added to each well and plate sealed with tape 
and incubated at 37°C for 1 hour. The wells were washed and 100 μl of reconstituted 
Horseradish Peroxidase (HRP) linked secondary antibody was added to each well. The plate 
was sealed with tape and incubated for 30 min at 37°C. 3,3′,5,5′-Tetramethylbenzidine (TMB) 
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Substrate (100 μl) was added to each well, sealed with tape and incubated   for 10 min at 37°C 
or 30 min at 25°C. Lastly, 100 μl of stop solution was added to each well. Absorbance was read 
at 450 nm within 30 min after adding stop solution using spectrophotometer. 
 
3.0 Statistical analysis 
Experiments were done in triplicates and all data presented as mean ± SEM. Statistical analysis 
was done using nonparametric test, Mann-Whitney U test or One way Analysis of Variance 
(ANOVA), to determine differences between groups and Dunnett’s test for post-hoc analysis, 
at 95% confidence interval, where p-value of p<0.05 was considered statistically significant, 
using Graph Pad Prism® Software version 7.0 San Diego, California. 
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Chapter Three 
RESULTS 
3.1 Chemistry  
A chalcone series of eleven compounds was successfully synthesized using the Claisen-Schmidt 
reaction. An intermediate compound, N-(3-acetylphenyl) cyclopropane carboxamide, was first 
synthesized by reacting 3-amino acetophenone with cyclopropane carbonyl chloride. The 
intermediate was reacted with differently substituted aldehydes to yield compounds 5a – 5k. 
The synthesized compounds fit very well in the hydrophobic binding pockets of AMPK (Fig. 
15). 
 
Table 2: Binding free energies of ligands docked onto AMPK (PDB code: 4CFH). 
 
 
 
The synthesized compounds showed characteristic peaks on IR, 1H-NMR and 13 C-NMR. They 
also presented good binding affinity to the enzyme as shown by binding free energies 
suggesting potential metformin-like antidiabetic effects (Table 2). 
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Figure 15. 5b-AMPK interaction (hydrophobic interactions shown in green). 
 
Spectrum 1: C-NMR and 1H-NMR of compound 5b 
 
                                                               A                                                                                     
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                                                                  B 
 
 
Figure 16. A: 13C-NMR spectrum of compound 5b. There are certain distinct peaks on the 
spectra that identify carbon atoms on the compounds. The peak appearing at ≈ δ 8 ppm on the 
13C-NMR spectras indicates the presence of the secondary carbon (CH2) of the 
cyclopropylcarbonyl amide. B: 1H-NMR spectra of compound. The chemical shift for all the 
CH2 protons on the cycloalkane resonated around δ 1.16 – 0.80 ppm as multiplets, while the 
other CH multiplet resonated around δ 1.62 – 1.58 ppm. 
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Spectrum 2: 1H-NMR C-NMR of compound 5k  
                                                        A       
                                                                   
B 
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Figure 17. A: 13C-NMR spectrum of compound 5k. Carbonyl group of the chalcone moiety 
shown by the yellow arrow, CH2 group of the cyclopropylcarbonyl amide shown by a green 
arrow and the CH group shown by a red arrow. B: 1H-NMR spectra of compound 5k, two CH2 
groups of the cycloalkane represented by blue arrows, CH group represented by the green arrow 
and the two sets of 3H on the methoxy groups represented by the red arrow. 
 
Spectrum 3: IR spectrum of compound 5b & 5k 
                                                                              A    
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B 
 
Figure 18. A: The IR spectra of compound 5b shows a consistent N-H stretch of the amide 
around wavelength number 3356.30 to 3249.67 cm-1. B: The IR spectra of compound 5k shows 
a consistent N-H stretch of the amide around wavelength number 3356.30 to 3249.67 cm-1. 
3.2 Biochemical assays 
3.2.1 Effects of chalcones on cell viability (MTT Assay) 
 
To determine the potential effects on cell viability and proliferation of chalcones 5b and 5k in 
C2C12 and Chang cell lines, cells were exposed to a range of concentrations (10 – 750 μM) 
for 12, 24 and 48 hours. Calculated IC50 values are shown in Table 4. IC50 is defined as 
concentration necessary to reduce the absorbance of treated cells (chalcones) by 50% compared 
to the control (untreated cells) [333] (Table 3).  
Cell viability of the compounds were inversely proportional to concentrations at three different 
time intervals (Fig.19). The IC50 values when C2C12 cells were exposed to treatment with 
Chalcone 5b at 12, 24 and 48 hours were 53.79, 13.97 and 32.83 µg/ml respectively.   
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Figure 19. C2C12 cells viability measured by MTT assays, expressed as percentage of the 
controls following exposure to compound 5b (10-750 μM) in cell culture media for 12, 24 and 
48 hours.  
The IC50 values when C2C12 cells were treated with compound 5k at 12, 24 and 48 were 26.59, 
8.44 and 20.99 µg/ml respectively (Fig. 20).  
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Figure 20. C2C12 cells viability was measured by MTT assays, expressed as percentage of the 
controls following exposure to compound 5k (10-750 μM)  in cell culture media for 12, 24 and 
48 hours. 
Compound 5b when exposed to Chang cells at 12, 24 and 48 hours has shown IC50 values of 
32.08, 34.97 and 50.07 µg/ml respectively to C2C12 treated cells (Fig. 21).   
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Figure 21. Chang cells viability was measured by MTT assays, expressed as percentage of the 
controls following exposure to compound 5b (10-750 μM) in cell culture media for 12, 24 and 
48 hours. 
The IC50 values when Chang cells were treated with compound 5k at 12, 24 and 48 were 25.38, 
18.04 and 33.26 µg/ml respectively (Fig. 22).  
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Figure 22. Chang cell viability was measured by MTT assays, expressed as percentages of the 
controls following exposure to compound 5k (10-750 μM) in cell culture media for 12, 24 and 
48 hours. 
Based on the findings from MTT assay, tested doses of cells that were incubated for 12 and 48 
hours with chalcones had reduced cell viability and higher IC50 values, hence the 
concentrations at 48 hours were selected for further studies.  
Table 3. Calculated IC50 values from MTT assays after the C2C12 cells were treated with 5b 
(2-chlorophenyl) and 5k (2, 3-dimethoxyphenyl) at three different time intervals. 
Chalcones Time (hours) n 
Mean 
concentrations 
(μM) ± SD of 
chalcones  IC50 (µg/ml) R-Squared 
C2C12- 5b 12 8 49.31 ± 0.05 53.79 0.9809 
  24 8 32.75 ± 0.08 13.97 0.9429 
  48 8 45.25 ± 0.12 32.83 0.9164 
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C2C12 - 5k 12 8 40.38 ± 0.06 26.59 0.9704 
  24 8 27.84 ± 0.09 8.436 0.9538 
  48 8 42.88 ± 0.22 20.99 0.7807 
            
Chang-5b  12 8 50.14± 0.12 32.08 0.9127 
  24 8 44.88 ± 0.06 34.97 0.9692 
  48 8 53.5± 0.05 50.07 0.9827 
            
Chang -5k 12 8 44.38 ± 0.12 25.38 0.9184 
  24 8 42.63 ± 0.08 18.04 0.9571 
  48 8 44.5± 0.08 33.26 0.9517 
 
3.2.2 Effects of chalcones on pAMPK activity  
 
Potential effects of chalcones 5b and 5k on AMPK were evaluated by analyzing the 
phosphorylated levels of the enzyme in total cell lysates by enzyme-linked immunosorbent 
assay. Interpolated concentrations of compounds were obtained from standard curves with 
corresponding absorbance values (Table 4). The magnitude of the absorbance, which was 
detected by development of the color, was directly proportional to the quantity of Phospho-
AMPKα (Thr 172) protein. The total protein content in lysates was determined by Bradford 
assays and standardized. 
 
Table 4: Calculated concentrations of pAMPKα (µg/ml) from standard curve  
 
  Chang   C2C12 
Concentration 
ABS (450 
nm) 
pAMPKα 
(µg/ml) 
ABS (450 
nm) 
pAMPKα  
(µg/ml) 
Controls (untreated cells) 
     
Controls  0.465 0.0810 0.359 0.0601 
 0.497 0.0875 0.396 0.0671 
 0.521 0.0925 0.468 0.0815 
 0.547 0.0980 0.531 0.0947 
Met (mM)     
2 0.812 0.1613 0.556 0.1000 
5 0.825 0.1650 0.655 0.1221 
10 0.847 0.1710 0.733 0.1410 
12.5 0.901 0.1867 0.806 0.1597 
NAR (µM)      
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50 0.511 0.0904 0.501 0.0883 
200 0.595 0.1084 0.556 0.1000 
300 0.681 0.1283 0.588 0.1069 
500 0.727 0.1393 0.648 0.1205 
     
Chalcone 5b (µM)                                                 
10 0.461 0.0802 0.403 0.0685 
50 0.504 0.0888 0.456 0.0792 
100 0.548 0.0982 0.468 0.0815 
200 0.574 0.1038 0.548 0.0983 
500 0.643 0.1194 0.573 0.1036 
Chalcone 5k (µM)     
10 0.484 0.0849 0.309 0.0507 
50 0.503 0.0887 0.387 0.0655 
100 0.508 0.0898 0.456 0.0792 
200 0.540 0.0964 0.487 0.0855 
500 0.553 0.0992 0.585 0.1062 
 
 
The model of the standard data was fitted using a polynomial curve of second order, which was 
for both Chang and C2C12 at 24 hours interval. Unknown concentrations of pAMPK were 
interpolated from standard curve using optical densities (Fig. 23).   
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Figure 23. Standard curve showing interpolated concentrations of pAMPK using quadratic 
curve fit, (dotted lines showing the 95% CI asymptotic). 
 
Metformin and naringenin significantly (p < 0.01 and P < 0.05, respectively) increased 
pAMPK levels compared to controls. However, cells exposed to co-treatment of chalcones 
with metformin and/or naringenin had significantly (Mt+5b, p < 0.0001; Mt+5k, p < 0.01; 
Nar+5b <0.05, p < 0.05 and Nar+5k, p < 0.05) increased pAMPK levels as compared to cells 
exposed to chalcones alone (Fig. 24). There were no significant differences in pAMPK levels 
between test compounds and the controls.  
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 Figure 24. Expression of pAMPK after exposure to naringenin, metformin and chalcones on 
Chang cell lines after 48 hours incubation. Cells harvested, lysed and equal amount of proteins 
were used for ELISA with specific antibody recognizing phosphorylated Thr 172. **p < 0.01; 
*p < 0.05 compared to controls, $p < 0.0001 compared  to 5b, ^p < 0.01compared to 5k, @p < 
0.05 compared to 5b and #p < 0.05 compared to 5k, respectively. Metformin (Mt), naringenin 
(Nar), 2-chlophenyl (5b) and 2, 3-dimethoxyphenyl (5k), phosphorylated-AMPK (p-AMPK).  
 
Metformin and or naringenin significantly (p < 0.01; P < 0.05), increased pAMPK levels 
compared to controls respectively on C2C12 cell lines. However, cells exposed to co-treatment 
of chalcones with metformin and/or naringenin had significantly (Mt+5b; p < 0.0001, Mt+5k; 
p < 0.01 and Nar+5b <0.05) increased pAMPK levels compared to cells exposed chalcones 
alone (Fig. 25). There was no significance increase in pAMPK activity in cells treated with 
naringenin plus compound 5k and compound 5k alone.  
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Figure 25. Expression of pAMPK after exposure to naringenin, metformin and/or chalcones 
on C2C12 cell lines after 48 hours incubation. Cells harvested, lysed and equal amount of 
proteins were used for ELISA with specific antibody recognizing phosphorylated Thr 172. **p 
< 0.01; *p < 0.05 compared to controls, $p < 0.0001 compared to 5b, ^p < 0.01compared to 5k 
and @p < 0.05 compared to 5b, respectively. 
 
Concentration-dependent expression of p-AMPK following exposure to metformin, naringenin 
and chalcones (Fig. 26 A and 27 A). Chang liver cells were more responsive to phosphorylated 
AMPK effects compared to C2C12 cells (p<0.05 compared to Chang cells) (Fig. 26 B). 
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Figure 26. A: Metformin concentrations plotted against the activities of phosphorylated 
AMPK-α in Chang and C2C12 cell lines, respectively and B: calculated Area-Under-the Curve 
expressed as AUC units (µg/ml X mM). * p<0.05 compared to Chang cells. 
 
Concentrations of chalcones were plotted against p-AMPK concentrations and concentrations 
of chalcones were directly proportional to concentrations of p-AMPK (Fig. 27. A). There was 
a significant difference in Chang-treated cells with Chalcones 5b and 5k compared to Chang-
treated cells with naringenin, (P <0.05 compared to Chang cells; # p <0.05 compared to Nar-
Chang cells). There was significant difference between C2C12-treated cells with chalcones 
compared to C2C12-treated cells with naringenin, (^ p<0.05 compared to NAR-C2C12 cells) 
(Fig. 27 B). 
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Figure 27. A: Concentrations of naringenin and its chalcones 5b and 5k plotted against the 
activities of phosphorylated AMPK in Chang and C2C12 cell lines, respectively and B: 
Calculated Area-Under-the Curve expressed as AUC units (µg/ml X mM). *p<0.05 compared 
to Chang cells; # p<0.05 compared to Nar-Chang cells; ^ p<0.05 compared to NAR-C2C12 
cells. 
 
Glycogen determination in Liver and Muscle cells  
 
The model of the standard curve was fitted using a linear regression curve to determine 
unknown glycogen concentrations, for both Chang and C2C12 at 48 hours interval. 
Interpolations were conducted from the fitted curve for more results of glycogen concentration 
and the model fitted on the data has a variation measure (r2 adjusted) of 99 07% (Fig. 28). 
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Figure 28. Glycogen standard calibration curve using fluorometric assay (dotted lines showing 
the 95% CI asymptotic). 
 
The glycogen levels in metformin and naringenin exposure were significantly (p< 0.05) 
decreased compared to untreated controls. Glycogen content in cells exposed to chalcone 5b 
was reduced similarly to metformin and naringenin. However, there was no significance 
difference in glycogen synthesis in test compound 5k compared to naringenin and metformin 
(Fig. 29).  
 
 
 
 
66 
 
c o
n t
ro
ls
M
e t
N
a r 5 b 5 k
0
1 0
2 0
3 0
4 0
G
ly
co
ge
n
(
g
/
g 
p
ro
te
in
)
T r e a tm e n t s  M
*
* @
 
 
Figure 29. Glycogen synthesis in Chang liver cells that were treated for 24 h with metformin, 
naringenin, and chalcones respectively. Data presented as mean ± SEM, each carried out in 
triplicates and glycogen content was measured by spectrophotometer to obtain optical 
densities. *p < 0.05 compared to controls, @p < 0.05 compared to control. 
 
Metformin and naringenin significantly (P< 0.05) decreased glycogen synthesis compared to 
controls in C2C12 cell lines. However, there was no significant decreases in glycogen synthesis 
in cells exposed to chalcones compared to metformin or naringenin (Fig 30).  
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Figure 30. 
Glycogen synthesis in C2C12 cells that were treated for 24 h with metformin, naringenin, or 
chalcones, respectively. Data presented as mean ± SEM, each carried out in triplicates and 
glycogen content was measured by spectrophotometer to obtain optical densities. *p < 0.05 
compared to controls. 
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Chapter Four  
4.1 DISCUSSION  
A number of patients fail to achieve optimum glycemic control with current medications hence 
there is an urgent need to continue working on the prevention and control of diabetes and its 
complications. In this regard, phytochemicals have recently attracted attention as source 
materials for the development of new potential therapeutic agents or alternative therapy for the 
management of diabetes and its related complications.  
Naringenin has been reported to have antioxidant, antiatherogenic, anticancer and antidiabetic 
effects [335]. In the current study, we chose an in vitro model to determine the putative effects 
of chalco- naringenin analogs on C2C12 and Chang cells. C2C12 and Chang cells derived from 
the murine C3H muscle myoblast and human liver lines, respectively, were used in the study 
since they have a complete compliment of glycogen metabolism [336].   
The Claisen-Schmidt condensation of acetophenones with aldehydes in the presence of a base 
or acid catalyst was the method used in the successful synthesis of 11 novel chalco-naringenin 
analogs. Although 11 chalcones were synthesized, only two analogs (compounds 5b & 5k) 
were used in the study because they were shown to fit very well in the hydrophobic binding 
pockets of AMPK as evidenced by docking results hence hypothesized to have metformin-like 
effects (Fig. 15).  The binding free energies of ligands docked onto AMP suggested that the 
chalcones had comparable binding affinities to naringenin and endogenous AMP. Compound 
5b had the highest biding affinity (-9.2 Kcal/mol) comparable to AMP and naringenin had a 
comparable binding affinity of -8.7 Kcal/mol.  
These binding affinities were close or comparable to endogenous AMP (-11.8 Kcal/mol) which 
is a second messenger that directly triggers activation of AMPK in increased ratios.  
The hydrophobic interactions may explain the less binding affinity observed for naringenin, 
which could be due to 3-OH groups present on the benzene ring thus makes naringenin less 
lipophilic with a reduced cell permeability. The pharmacophore of the test compounds is 
related to that of naringenin, which has been shown to bind to and activate AMPK hence 
suppression of blood glucose. 
The compounds showed characteristic peaks observed on IR, 1H-NMR and 13C-NMR as shown 
by (Fig. 16-18) for 5b and 5k. On the 1H NMR spectras, as expected, all compounds showed 
characteristic peaks for cycloalkane CH2 protons at around δ 1.16 ppm as multiplets and the 
CH proton of the cycloalkane resonated around δ 1.62 ppm. The disappearance of signal of 
methyl protons and the appearance of new proton signals in the aromatic region confirms the 
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formation of chalcones (CH=CH). 13C NMR also allowed characterization of the compounds, 
a distinct characteristic peak of the carbonyl group carbon found on the chalcone moiety, 
resonated around δ 190 ppm.  
On the other hand, the other two characteristic peaks appeared on the cyclopropylcarbonyl 
amide substitution where the CH2 group resonates around δ 8 ppm and the carbon of CH 
observed at around δ 15 ppm. Absence of methyl carbon signal, appearance of alkenic signals 
and aromatic carbons confirmed the product formation.  
Docking of molecules on the active site of AMPK gives pharmacological insights on the 
potential in vivo and in vitro binding affinity of these molecules. Molecules with a high binding 
affinity in silico are more likely to bind to the target in vivo. The results from the docking scores 
suggest that compound 5b is more likely to bind to the active site of AMPK. This further 
indicates the likelihood of compound 5b as potential putative therapeutic agent in glycemic 
control that could be due to activation of AMPK, hence the aim of the present study. 
AMPK is the regulator of diverse metabolic pathways and functions as a cellular gauge hence 
its actions on glucose metabolism make it an attractive target in the management of T2D [337]. 
It down-regulates hepatic glucogeonegenic enzymes and facilitates glucose transport into 
skeletal muscles. Attenuation of hyperglycemia is a major treatment goal for the management 
of diabetes. Given the hypothesized relation between anti-inflammatory, anti-dyslipidemia and 
the potential for naringenin to protect the body against free radicals and other pro-oxidative 
compounds, it is likely that consumption of naringenin may have a great potential in 
management of metabolic disorders.  
Therefore, given the evidence from docking results, AMPK could be a potential target for 
synthetic chalco-naringenin analogs that could then result in therapeutic applications including 
management of metabolic disorders. Cells were exposed to different concentrations of 
chalcones (10-750 µM) and from these results cell viability was inversely proportional to 
concentrations at all-time intervals (Fig. 19-22). Cell viability of chalcones was compared to 
control (untreated cells). In this study, we endeavored to calculate IC50 values of newly 
synthesized chalco-naringenin analogs as potential agents for AMPK target on C2C12 and 
Chang cell lines. 
Compound 5b when exposed to Chang cell lines showed higher IC50 value of 50.07 µg/ml at 
48 hours pre-incubation, which could be because of less deleterious effects compared to 12 and 
24 hours (Table 3).  
Cell survival in low concentrations of chalcones 5b and 5k (10, 20 and 30 μM) indicated no 
significant decrease in cell viability compared to control (100%), but at higher concentrations 
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(200-750 μM) cell viability decreased sharply after 24 hours of incubation. Treatment of Chang 
and C2C12 cells for 12 and 48 hours with chalcone 5b and 5k increased cell viability, as 
determined by the MTT assay, indicating that the concentrations selected for the study had less 
deleterious effects during the pre-incubation (Table 3). However, at 24 hours incubation period, 
cell viability was dropping rapidly on C2C12 cells. This is also evidenced by IC50 values of 
13.97 µg/ml and 8.43 µg/ml for compound 5b and 5k, respectively (Fig. 19 and 20).   
The results demonstrated that there were significant differences in IC50 values of each 
compound against C2C12 and Chang cell lines (Tables 3). The estimated IC50 values suggested 
that chalcone 5b showed relatively low cytotoxic effects on both cell lines at three time 
intervals compared to 5k on both cell lines. However, both compounds did not evoke changes 
in cell viability, especially on Chang cells as compared to C2C12 cells (Fig. 19 and 21). From 
this results the conclusion can be made that the test compounds presented with higher cell 
viability and IC50 values on Chang cell lines as compared to C2C12 cell lines. 
This was further evidenced by IC50 values estimated which were higher on Chang compared to 
control (Table 3). At 48 hours exposure, there was a significant increase in cell viability for 
both cell lines, which could be advocated to proliferative properties of cells and the 
preservation of the regular cell cycle. Hence it was suitable for further assays. Cell viability of 
compounds was reduced in a concentration dependent manner (Fig.19-22) and these trends 
were consistent with previous studies reported on naringenin [338]. 
Collectively, our results indicated that tested compounds (5b and 5k) showed remarkably lower 
toxic activity in vitro compared to controls (IC50 between 8.43- 53.79 µg/ml). The test 
compounds were exposed to cells for 48 hours for measurement of phosphorylated AMPK and 
glycogen synthesis. Metformin was used as a positive control in our study since we 
hypothesized that the synthetic analogs of naringenin exert similar effects to the well-known 
drug by AMPK mediated-pathways. Metformin has been shown to reduce glucose production 
either by decreasing gluconeogenesis and glycogenlysis through AMPK activation [231]. The 
postulated mechanisms of action to suppress gluconeogenesis include inhibition of uptake of 
gluconeogenic precursor lactate, inhibition of rate limiting enzymes (PEPCK and G-6Pase) and 
increased flux through pyruvate kinase secondary to decreased cellular ATP content [265]. 
There is substantial evidence suggesting that metformin suppresses hepatic gluconeogenesis 
by increasing AMPK activation [188, 229]. Therefore, compounds such as naringenin that 
activate AMPK may play a significant role in glucose homeostasis hence the study investigated 
the effects of chalco-naringenin analogs on the expression of p-AMPK in vitro. 
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The C2C12 and Chang cells were exposed to different concentrations of naringenin, metformin 
and chalcones for 24 hours. The protein expression of p-AMPK was significantly increased 
(p< 0.01) in metformin treated cells at concentrations (2-10 mM) as compared to control (Fig. 
24 and 25). Previous studies that have shown that metformin activate AMPK by increasing the 
phosphorylation of AMPKα at Thr-172 in primary hepatocytes which could be through 
inhibition of the respiratory chain complex [233, 328, 342]. 
 A subsequent study showed that hepatic knockout of LKB1, the upstream kinase for AMPKα 
phosphorylation at Thr172, abolished metformin suppression of hepatic glucose production 
that then suggests that activity of LKB1 is constitutive by promoting AMPK activation [343]. 
Although metformin is known to activate AMPK through LKB1 phosphorylation, it is unclear 
how the glucose-lowering effects are related to AMPK activation [344]. Inhibition of the 
respiratory chain complex 1 results in decreased cellular ATP synthesis thereby increasing 
cytosolic ADP: ATP ratio and consequently, an increase in AMPK activation, which in turn is 
associated with decreased gluconeogenesis [345].  
Increased AMP levels lead to activation of AMPK, but this does not necessarily imply that 
AMPK mediates the therapeutic actions of metformin, as AMPK has multiple cellular targets. 
This study reports the potentiated effects of metformin plus test compounds on both cell lines 
evidenced by significantly elevated levels of pAMPK (p<0.05) compared to cells treated with 
chalcones alone (5b and 5k) only (Fig . 24 and 25).  
The results show that metformin somehow enhances the effects of compounds 5b and 5k but 
the raised question is “how does metformin plus chalcones when exposed to cells in culture 
increase levels of phosphorylated AMPK?” Further studies could be carried out to clarify the 
phenomena and hence provide new insights into potential role of chalcones as putative 
therapeutic agents through AMPK mediated pathways. Treatment of Chang and C2C12 cell 
lines with naringenin also significantly increased phosphorylation of AMPK compared to 
control (p <0.05) (Fig. 24 and 25). The findings are in agreement with previously published 
studies by Zygmunt et al. (2010) who investigated direct effects of naringenin on skeletal 
muscle glucose uptake and the mechanism involved, further reported that antidiabetic effects 
of naringenin might be AMPK-mediated [337]. Hajiaghaalipour et al. (2015) also reported that 
antihyperglycemic effects of naringenin are mediated by downregulation of hepatic PEPCK 
and G6Pase respectively thus supporting findings of the present study [346]. Therefore, 
because of these beneficial effects of naringenin in attenuation of hyperglycemia and related 
complications, further investigations can be made for mechanisms at cellular and molecular 
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level. There was no significant increase in levels of pAMPK in cells treated with naringenin 
and chalcone 5b and 5b only (Fig. 26 and 25). 
The findings are similar to that of metformin when compound 5b was added to it, therefore we 
can conclude that the effects which were seen were that of naringenin or metformin. These 
results suggest that the effects of chalcones did not enhance the effects of naringenin or 
metformin rendering opportunity to further explore chalcones in-vivo iv-vitro again and later 
in clinical trials. However, compound 5k when co-exposed to both cell lines with naringenin 
did not have any significant difference in phosphorylated AMPK (Fig. 24 and 25).  
Additionally, there was no significant difference of phosphorylated AMPK in test compounds 
as compared to controls (p>0.05) (Fig. 24 and 25). Furthermore, metformin concentrations 
were plotted against the activities of phosphorylated AMPK-α in Chang and C2C12 cell lines 
to calculate the Area-Under-the Curve (AUC). Metformin had the larger AUC, which suggests 
that metformin caused activation and upregulation of p-AMPK more compared to naringenin 
and chalcones (Fig 26 and 27). The results also indicated that induction of AMPK activity was 
more pronounced in the Chang cell lines compared to C2C12 (p <0.05) (Fig. 26. B). Although 
metformin effects on AMPK have been shown to be more pronounced, naringenin and its 
synthetic analogs nonetheless had effects on AMPK even though they were significant to a 
lesser extent (Fig. 27 A and B). There was significant difference of p-AMPK in NAR-Chang 
cells than NAR-C2C12 cells suggesting that, there was more up-regulation of AMPK by 
naringenin in Chang cells than C2C12 cells (p < 0.05) (Fig 27 B). 
Although the chalcones are analogs of naringenin, their putative therapeutic applications could 
as well be through non-AMPK mediated pathways. The pharmacophore of chalcones is similar 
to that of naringenin but that does not render chalcones mechanism of action to be similar to 
naringenin. Moreover, the decreased significant difference of chalcones as compared to control 
could be due to concentrations of test compounds used (10-500 µM) therefore, we anticipate 
that high concentrations and/or longer-term experiments might be required in order to see 
effects of chalcones on AMPK in cells or tissues.  
Glucose uptake assays were not performed to compare the magnitude of suppression of glucose 
metabolism by naringenin and/or metformin to that of chalcones hence future studies using 
primary cell lines and in-vivo models may help to clarify the effects of chalco-naringenin 
analogs on glucose uptake. 
 It was reported that naringenin stimulated glucose uptake when exposed to myotubes by 
inhibiting the activity of PI3K, a key regulator of insulin-induced GLUT 4 translocation, as 
shown by impaired phosphorylation of the downstream signaling molecule Akt [287, 347]. 
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Metformin has been shown to stimulate glucose uptake through AMPK activation, however, it 
has also been shown to reduce elevated levels of FFA that increases hepatic glucose production 
and peripheral insulin resistance through AMPK independent mechanisms [231]. Therefore, it 
is possible that AMPK-independent actions of metformin can reduce circulating plasma FFA 
levels and contribute to reduced rates of gluconeogenesis without AMPK hence we hypothesize 
that the chalcones can reduce hepatic glucose production by similar mechanisms.  
Moreover, naringenin also significantly reduced plasma and hepatic lipids, normalized glucose 
tolerance and insulin sensitivity independent of AMPK, hence enhanced glucose uptake in 
skeletal muscles [348]. More in vitro studies could be carried out to firmly establish the role of 
AMPK in mediating effects of chalcones. Treated cells with chalcones could be co-incubated 
with AMPK inhibitors, the most commonly used compound C to exhibit significant inhibition 
of several structurally related kinases to AMPK including  PKCθ, PKA and Janus kinase 3 
(JAK 3).  
Additional studies will be required to further elucidate potentiated effects of metformin and 
naringenin when co-treated with chalcones on inhibition of hepatic glucose production [188]. 
Thus, the observed association of increased AMPK activity when cells were treated with test 
compounds plus metformin and naringenin can suggest that AMPK could be a potential target 
for synthetic chalco-naringenin analogs. 
Glycogen is the principal storage form of glucose in animal and human cells which is highly 
branched and made of α (1, 4) linkages with α (1, 6) linkages occurring every 8-10 glucose 
units along the backbone [349]. Glycogen is synthesized primarily by the liver and skeletal 
muscles, but it can also be made in other organs. Glycogen  content  can  be  significantly  
altered upon  disruption  of  glucose  homeostasis in  metabolic  syndromes,  such  as  diabetes 
[349]. 
The liver plays a critical role in maintaining blood glucose concentrations both through its 
ability to supply glucose to the circulation via glycogenolysis and gluconeogenesis in the post-
absorptive state and to remove glucose from the circulation after meal ingestion [350]. 
Glycogen determination was estimated using anthrone reagent as described by Seifter et al. 
(1949). The linear regression curve was used to calculate unknown glycogen concentrations 
from absorbance values obtained by a spectrophotometer.  
Metformin significantly decreased glycogen synthesis as compared to control (p <0.05) (Fig. 
27 and 28). Previous studies have also demonstrated that metformin decreases glycogen stores 
in dose-dependent manner in cultured hepatocytes [349, 351]. Metformin is known to have 
74 
 
beneficial effects on body weight and body composition, although the precise mechanism is 
unclear.  
Metformin enhances uptake of glucose without prompting gluconeogenesis, however AMPK 
activation channels ATP synthesis towards utilization not glucose storage hence decreased 
glycogen stores. These could then explain why metformin reduces body weight hence obesity 
in T2D. Metformin has been shown to cause accumulation of AMP in the liver, resulting in the 
inhibition of adenylate cyclase [351]. The reduction of cAMP levels and PKA activity 
suppresses glucagon-induced gluconeogenesis in the liver. In addition, naringenin and 
chalcone 5b significantly decreased glycogen synthesis in Chang cell lines compared to control 
(p <0.05) (Fig. 27).  
However, in C2C12 cell lines there was no significant decrease in glycogen synthesis when 
cells were treated with chalcones. Chen et al. (2015) reported that flavonoids increase the 
glucokinase level, thus promoting glycogen synthesis to reduce G6Pase and 
phosphoenolpyruvate carboxykinase gene expression, thus inhibiting gluconeogenesis or 
glycogenolysis or both [353]. Unlike metformin, which could reduce glycogen synthesis by 
glucose utilization, naringenin could enhance glucose uptake but in different molecular 
mechanism to metformin (Fig. 27). Mulvihill et al. (2009) had reported that naringenin reduces 
lipid accumulation and promotes glucose uptake, however it does not act directly in the skeletal 
muscle therefore reduced muscle lipid and improved glucose utilization could be due to 
reduced lipoprotein uptake. They further demonstrated that naringenin prevents 
hyperinsulinemia, stimulate lipogenesis, and activates hepatic fatty acid oxidation resulting in 
prevention of hepatic triglyceride accumulation and subsequently normalization of VLDL 
overproduction that leads to amelioration of dyslipidemia [348].  
 Although we hypothesize that chalcones could enhance glucose uptake, in the present study 
the test compounds did not significantly decrease glycogen synthesis as compared to metformin 
in the skeletal muscles cells. Collectively, these findings demonstrate that chalco-naringenin 
analogs especially 5b could have remarkably favorable effects on AMPK expression, although 
further studies could be carried out to determine their cellular and molecular mechanisms and 
their potential in glucose uptake. 
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Chapter Five  
5.1 CONCLUSION 
Emerging evidence from various, epidemiological, animal and in vitro studies have confirmed 
the beneficial effects of dietary flavonoids in the treatment and management of T2D and its 
related complications through AMPK activation. We have showed that chalco-naringenin 
analogs could have potential in expression of AMPK through computational chemistry 
technique. However, when using an in-vitro cell culture based model chalcone 5b showed more 
potential compared to 5k when added to metformin or naringenin. Chalcones did not have 
antagonizing effects when co-exposed with naringenin and metformin. MTT assay was also 
done to measure cell viability and proliferation of newly synthesized chalco-naringenin analogs 
and 5k had reduced cell viability compared to compound 5b on Chang and C2C12 cell lines. 
Calculated IC50 suggested low toxicity on compound 5b however, some toxicity studies can be 
done in future since the compounds are newly synthesized.  
5.2 Future studies 
The study recommends future work using primary hepatocytes and in vivo-studies to clarify 
the mechanisms and develop therapeutic targets for the effective management of diabetes and 
associated complications.  
5.3 Limitations of study 
In the present study, the analogs did not have a prominent impact on AMPK as shown by 
docking studies. The rationale could be because of low concentrations of chalcones used in 
experiments and or pipetting errors, which could have resulted to lower efficacy of compounds.  
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